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ABSTRACT
Background
Cardiovascular disease (CVD) remains the number one killer even after years of
advances and preventative measures. Identifying and reducing modifiable risk factors
is a health care priority. CVD Risk assessments are calculated using several traditional
risk factors including age, gender, race, blood pressure, cholesterol, history of diabetes,
and smoking to estimate a persons’ risk of developing CVD (heart disease or stroke) in
the next 10-years. In addition to the traditional risk factors for CVD, there is increasing
evidence of metabolic disorders, depressive symptoms, inflammation and sleep quality
posing a greater risk for CVD. However, these factors are not included in the current
risk prediction models including the Framingham Risk Score, Reynolds Risk Score, and
Pooled Cohort Risk Equations. Therefore, this study examined the effect of depressive
symptoms, inflammation, and sleep quality on the independent risk for CVD.
Objective
The primary objective of this study was to evaluate the independent relationships
between traditional cardiac risk factors, depressive symptoms, inflammation, and sleep
quality, on long-term risk of major adverse cardiovascular events (MACE). The
secondary objective was to evaluate whether gender modifies the relationships between
depressive symptoms, inflammation, and sleep quality on long-term risk of MACE.
viii

Design
A secondary analysis was conducted on data obtained from the Longitudinal
prospective cohort study Heart Strategies Concentrating on Risk Evaluation (Heart
SCORE) conducted by the University of Pittsburgh. The ongoing Heart SCORE study
has been prospectively examining cardiovascular disease (CVD) risk factors and CVD
events on an initial cohort of 2,000 enrolled adults ages 45 to 75 at study entry. A Cox
proportional-hazard model was used to evaluate the relationship between traditional risk
factors as well as independently and collectively for depressive symptoms, inflammation
and sleep quality and risk of MACE. Models were reanalyzed adding gender as an
interaction term and in stratified analyses to evaluate whether gender modifies the
relationships between sleep quality, depressive symptoms, and inflammation and longterm risk of MACE.
Results
The participants (N= 1,895) included in this study were, 1256 females (66%), 639
males (34%), ranging from 45 to 75 years of age with a median age of 60 years, 42%
Blacks, 55% Whites and 3% other race. Six percent, (n =113) of the participants
experienced a major cardiac event during a mean of nearly 10 year follow up. Results
indicated that men as compared with women with high levels of interleukin-6 had
particularly high risk for CVD, as defined by two separate definitions of MACE, MACE1:
Hazard Ratio (HR) 3.44 vs. 1.72 for males and females, respectively, MACE6: HR 2.51
ix

vs. 1.69 for males and females, respectively. These results suggest the high
inflammation in men is strongly associated with future risk of CVD. The addition of
depressive symptoms to the initial traditional risk factor model was associated with a
modest increase in the risk of both definitions of MACE (HR range from 1.20 to 1.68)
with similar results observed by gender. Sleep quality/Insomnia was not associated with
long-term risk of MACE overall or when evaluated separately by gender.
Conclusion
Primary prevention with early identification of potential modifiable risk factors is a
key strategy in planning interventions to reduce the risk of CVD. Results from this study
suggest that depression and inflammation (e.g. IL-6) should be studied in other
populations to estimate their independent predictive value in risk stratification. Whereas
sleep quality was not associated with long-term risk of CVD in this analysis, future
studies should consider the use of objective measures of sleep quality, such as
actigraphy in addition to standard use of self-report measures and sleep diaries.
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CHAPTER ONE:
INTRODUCTION
Cardiovascular disease (CVD) is the number one cause of death worldwide, with
an estimated cost of $316 billion per year (Benjamin et al., 2018). Cardiovascular
disease is a broad term used to include any ailment of the heart and vascular system
(Center for Disease Control and Prevention, CDC, 2018). The Agency for Healthcare
Research and Quality (AHRQ) has elevated cardiovascular disease prevention and
treatment as national priority in the National Quality Strategy (AHRQ, 2014). The Million
Hearts Campaign initiative aims to prevent one million heart attacks and strokes over a
5-year period with an objective to identify and spread better models of care delivery and
payment (Benjamin et al., 2018).
Although several multivariable risk estimation scores and equations have been
derived and published, there are inherent limitations of using the existing scores (Goff et
al., 2014). In addition, data are sparse on the use and impact of absolute risk scores in
clinical practice in primary-prevention settings to determine absolute risk score for
varying populations of the United States (Goff et al., 2014). Risk factor determination
using the existing CVD risk assessment models may predict the incidence of CVD
events and mortality. However, many experts believe that there is a need to identify and
add novel risk markers in short- and long-term risk assessment to determine outcomes
in all racial/ethnic groups, and across the age spectrum, and in women and men (Lin et
1

al., 2018). The short- and long-term risk assessment in diverse groups will guide
providers to offer a more personalized approach to patient behavioral and motivating
interventions, change and adherence to therapy for improving risk factor levels, and
clinical outcomes (Lin et al., 2018).
The US Preventive Services Task Force (USPSTF) recently published
recommendations regarding the use of non-traditional risk factors in CVD risk
assessment (Curry et al., 2018). The focus of the most recent recommendations was
on the ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) level, and
coronary artery calcium (CAC) score (Benjamin et al., 2018; Curry et al., 2018; Lin et
al., 2018). When endorsing change of health benefits, potential harms and cost are
considered. Although, the impact of these risk factors was not consistent nor significant
enough to recommend reform from current practice, the potential benefits were
recognized and may be considered in a more personalized approach for prevention and
treatment (Benjamin et al., 2018; Curry et al., 2018; Lin et al., 2018).
Evidence is also emerging that other non-traditional risk factors such as
depressive symptoms and sleep quality may increase susceptibility and aid in
subsequent prediction for CVD (Alcantara & Davidson, 2014; Sands-Lincoln et al.,
2013). In general, most cohort studies that assessed risk calibration with the use of
novel markers found that adding one of the non-traditional risk factors improved
calibration and potentially better preventive care (Curry et al., 2018). Therefore, using
existing data set from Heart Strategies Concentrating on Risk Evaluation (Heart
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SCORE) study, this secondary data analysis focused on examining the contribution of a
few key non-traditional risk factors, on predicting long-term risk of CVD.
Background of the Problem
National and worldwide initiatives in the development of risk assessment tools
have resulted in improved treatment guidelines, including use of medications and
invasive interventions that have played significant roles in the reduction of CVD
mortality (Benjamin et al., 2018). Traditionally, prevention and management of CVD
begins with an assessment to identify the presence of cardiac risk factors (Benjamin et
al., 2018; Curry et al., 2018). The risk factors are conditions that, on average, make a
person more likely to develop a disease. Such risk factors for CVD are categorized into
modifiable or non-modifiable risk factors. Modifiable risk factors for CVD include: high
blood pressure, diabetes, hypercholesterolemia, obesity, sedentary lifestyle, smoking,
uncontrolled stress, and unhealthy dietary habits (Benjamin et al., 2018). Age, family
history of early heart disease and menopause for women are risk factors that cannot be
changed to reduce the likelihood of CVD, and thus, are termed non-modifiable risk
factors (Benjamin et al., 2018).
Primary care providers are responsible for identifying modifiable risk factors and
management of preventive interventions including education and life-style changes
(AHRQ, 2014). However, studies have used different stratum and risk calibration
approaches to determine risk (Curry et al., 2018). In this regard, although the addition
of some non-traditional risk scores improved calibration, there is inconsistent evidence
as to the benefits of basing therapeutic strategies on some of the non-traditional risk
3

factors for patients; for example, adding statin therapy for patients with elevated hsCRP
levels (Ridker et al., 2008). As clinical practice moves toward a single threshold
(algorithm) for treatment, this concern may no longer be relevant in clinical decision
making. The USPSTF recommends including more information on the differences
between commonly used CVD risk assessment tools, as well as population distribution
of risk (Curry et al., 2018).
History of Cardiac Risk Assessment
The original CVD risk assessment was developed for adults between the ages of
30 to 62 at the time of first examination, and with no history of heart attack or stroke.
These assessments were derived from participants enrolled in the Framingham Heart
Study, which began in 1948 (Kannel, 1976). The Framingham Heart Study, along with
other important large studies, such as the Seven Countries Study and the Nurses’
Health Study, provided the information now known about cardiac risk including healthy
lifestyle such as healthy diet and regular exercise (Kannel, 1976). Additionally, greater
knowledge about the differences in cardiovascular risk between men and women were
gleaned from these studies. The first risk prediction equations demonstrated the
potential amplified risk when having multiple risk factors such as, hypertension, elevated
total cholesterol, decreased HDL, smoking, glucose intolerance, and left ventricular
hypertrophy, versus one risk factor (O’Donnell & Elosua, 2008).
The CVD Risk assessments are calculated using several factors including age,
gender, race, blood pressure, cholesterol, history of diabetes, and smoking to estimate
4

a persons’ risk of developing CVD (heart disease or stroke) in the next 10-years. The
overall goals of these tools are to assist not only clinicians, but also patients, in
understanding risk and monitoring over time and quantifying potential benefits of
preventative therapies (Benjamin et al., 2018; Curry et al., 2018; Lin et al., 2018).
The Framingham Risk Score
The Framingham Risk Score (FRS) assessment is a well-known and widely
accepted tool, developed from the knowledge gained in the long-term Framingham
Heart Study. The FRS uses a simple point score to provide 10-year estimates of
myocardial infarction or cardiac mortality (Hermansson & Kahan, 2018). The first
Framingham risk score was introduced in 1976 and identified risk factors successful at
predicting 10-year risk for CVD. This study validated non-modifiable risks such as age,
gender, family history and previous history of cardiac problems and modifiable risk
factors including smoking, diabetes, hyperlipidemia, and hypertension (Hermansson &
Kahan, 2018; Kannel,1976). The Tool was updated in 2002 with the addition of
dyslipidemia, and in 2008 with the addition of diabetes as a major risk factor
(Hermansson & Kahan, 2018). The FRS tool has been questioned for its generalizability
to the general American population, as it was developed and tested on a primarily White
male population.
Reynolds Risk Score for Women
The Reynolds Risk Score for Women (RRSW) was developed to overcome the
drawback from FRS with gender-specific assessment. The RRSW includes assessing
activity, lifestyle, and diet, and includes a measure of the inflammatory marker C5

Reactive Protein (CRP) (Goff et al., 2013). The RRSW was developed from findings of a
large study with over 24,000 healthy non-diabetic women. These women were followed
over 10 years and monitored for the development of a major cardiac event (Ridker et
al., 2007).
Reynolds Risk Score for Men
The Reynolds Risk Score for men was developed based on a study following
over 10,000 healthy non-diabetic men over 10 years. Like the women’s tool, the addition
of High Sensitive C-Reactive protein (hsCRP) and family history of a major event prior
to the age of 60 years of age was added to the model improving predictability of CVD in
men (Ridker et al, 2008).
Pooled Cohort Equations Risk Estimator
Through collaborative efforts of the AHA, National Heart, Lung and Blood
Institute (NHLBI) and The American College of Cardiology, the Pooled Cohort
Equations Risk Estimator tool was developed to better predict the 10-year risk of
developing atherosclerotic cardiovascular disease (ASVCD) and how that risk may
change over time as preventative measures are initiated (Goff et al., 2013). Attention
was taken to include various races and gender within this study (Goff et al, 2013). The
Pooled cohort screen is presently recommended as the standard of practice for risk
screening. Unlike the Reynolds score but similar to the FRS, the Pooled Cohort
Equations tool includes diabetes as a risk factor, highlights the large burden of disability
from non-fatal cardiac events and provide separate equations for non-White
populations. Yet, given the increased evidence that inflammation plays a crucial role in
6

the process of atherogenesis, the Pooled Cohort Equations do not include CRP or other
inflammatory markers in risk calculation (Held et al., 2017; Joseph et al., 2017).
Many developing countries have developed CVD risk scores specific for their
region such as the Canadian CVD guideline (Anderson et al., 2012); The European
Society of Cardiology uses the Systemic Coronary Risk Evaluation (SCORE) risk charts
(Perk et al., 2012); The UK National Institute for Health and Care Excellence uses the
QRISK3 risk tool; and The Scottish Intercollegiate Guidelines Network (SIGN) uses the
ASSIGN risk score to determine the 10-year risk of a CVD events (National Institute for
Health and Care Excellence (NICE), 2014). These risk assessments tool do not include
non-traditional risk scores such as hsCRP (Scottish Intercollegiate Guidelines Network
(SIGN),2017).
The above-mentioned risk scores are algorithms that enable health care
providers and patients to estimate 10-year and lifetime risks for atherosclerotic CVD to
provide preventive services to minimize the risk (Bell & Saraf, 2014). Unfortunately,
there is insufficient data to reliably predict risk for those less than 40 years of age or
greater than 79 years of age (Curry et al., 2018). Also, evidence is emerging on the
association of metabolic disease, depressive symptoms, and sleep quality that
increases CVD risk, and these are not included in the above risk prediction tools,
thereby warranting further studies. Thus, this secondary analysis aimed to examine the
value of these non-traditional risk factors in risk prediction.

7

Problem
Despite a wide range of educational programs, national campaigns, increased
funding and improved screening tools, CVD continues to have very high mortality and
burden of disability on society. Nearly half of all Americans (44%) have at least one of
the three key risk factors for heart disease: high blood pressure, high cholesterol, or
smoking (Benjamin et al., 2018). Moreover, the growing obesity epidemic is associated
with unhealthy diet, high blood pressure and a dramatic rise in Type 2 diabetes
(Benjamin et al., 2018).
Over the past 2 decades, considerable progress has been made in the reduction
of CVD related deaths, with a decrease of nearly 3.79% from 2000 to 2011 (Sidney et
al., 2016). However, the decline flattened around 2011 and remains flattened today
(Mensah et al., 2017; Sidney et al., 2016). The annual rate of decline for CVD mortality
between 2000-2011 was 3.79 percent, while the same measures from 2011-2014 were
only less than one percent (Sidney et al., 2016). The current risk reductions
recommendations are based mostly on the risk assessment with the Framingham Risk
Score or Pooled Cohort Equations. Quality studies comparing traditional risk
assessment with traditional risk assessment together with novel markers such as
cytokines are needed to measure the potential impact of adding nontraditional risk
factors on clinical decision thresholds and patient outcomes (Shaima, Vinayaga-Moorthi
& Kutty-Shaheen, 2016).

8

Purpose
Depressive symptoms have been linked to CVD and CVD mortality (Lahtinen et
al., 2018; Lawes et al., 2018). Additionally, persons with high levels of inflammatory
markers and altered sleep quality have also been identified as being at a higher risk of
CVD (Dhar & Barton, 2016). These modifiable risk factors are not traditionally screened
for and may contribute to both primary and secondary prevention for cardiac disease
aimed at reducing risk for CVD and limiting complications, mortality, and disability,
including among those who have experienced a major adverse cardiac event.
The purpose of this secondary data analysis was to evaluate the predictive ability
of depressive symptoms, inflammation, and sleep quality on CVD risk. An additional
clinical question was to determine, if screening for these non-traditional modifiable risk
factors during routine exams, may allow for primary prevention measures that may
reduce risk of CVD. This included evaluation overall and by gender.
Specific Aims:
1. To prospectively evaluate the independent relationships between traditional
cardiac risk factors, depressive symptoms, inflammation, and sleep quality, on
long-term risk of major adverse cardiovascular events (MACE).
2. To prospectively evaluate whether gender modifies the relationships between
depressive symptoms, inflammation, and sleep quality on long-term risk of
MACE.

9

Definition of Terms
For purposes of this study, the following terms are defined:
Cardiovascular Disease
Cardiovascular disease (CVD) is a global term that refers to conditions that involve
the heart and vascular system. This includes a diagnosis of congenital malformations of
the heart and/or vasculature, hypertension, arrhythmias or irregular electrical activity of
the heart, valvular heart disease and ischemic heart disease or arthrosclerosis (Benjamin
et al., 2018). For this study, persons with congenital malformations were not included.
Major Adverse Cardiac Event
Major adverse cardiac event (MACE) is a composite endpoint commonly used in
research, yet without a standard definition (Kip et al., 2008). The Heart SCORE study
employed 6 different definitions for MACE. To illustrate a lack of standard definition and
end points for MACE, deJung et al. (2017) defined "CVD events” as admission for heart
failure, ischemic cardiovascular events, and cardiac death. In a dissimilar manner,
Nejatian et al. (2017) defined MACE as a hospital stay with an MI, unplanned
revascularization including percutaneous coronary intervention, coronary artery bypass
surgery and all-cause mortality (deJung et al., 2017; Nejatian et al., 2017). Within the
current analysis, two of the six definitions of MACE were examined, as defined below.
MACE1. MACE1 includes, all cardiac deaths, acute myocardial infarction, (AMI),
cerebral vascular accident (CVA), acute ischemic syndrome (AIS) and any coronary
revascularization procedure.
10

MACE6. MACE6 includes all deaths, acute myocardial infarction, (AMI), cerebral
vascular accident (CVA), acute ischemic syndrome (AIS).
Atherosclerosis
Atherosclerosis, also known as atherosclerotic heart disease (ASHD), involves a
buildup of plaque inside arteries leading to a narrowing and stiffening of the vasculature.
The plaque is made up from cellular waste, fatty deposits, calcium, and fibrin (Benjamin
et al., 2018). Vascular narrowing slows the flow of oxygenated blood and increases the
risk of blood clot formation. Additionally, plaque can break away from the arterial wall,
increasing risk for a thrombus or obstructed blood flow (Benjamin et al., 2018).
Atherosclerosis increases risk of organ failure due to diminished oxygenated blood flow.
Ischemic Heart Disease
Ischemic heart disease is a condition in which buildup of plaque within the walls
of the coronary arteries causes narrowing within the size and compliance of the
vasculature creating an obstructed blood flow. The reduced blood flow results in
reduced oxygenation or ischemia to the heart muscle and organs (Benjamin et al.,
2018).
Cardiac Events
Cardiovascular events include the diagnosis of death related to cardiac disease,
myocardial infarction, acute ischemic syndrome, cerebral vascular accident (ischemic),
and ischemic heart disease requiring revascularization or opening of the arteries to
increase blood flow. Ischemic heart disease and cardiovascular events are of interest
for this study.
11

Myocardial Infarction (MI)
The most common cause of an MI is atherosclerosis that has led to a complete
blockage of blood flow to an area of the heart (Benjamin et al., 2018). Additional
terminology includes ST-elevation myocardial infarction (STEMI) and non-ST-elevation
myocardial infarction (NSTEMI). These terms are based on presentation of a MI on an
electrocardiogram (ECG) (Kumar & Cannon, 2009; Senter & Francis, 2009).
Revascularization
Revascularization refers to any medical procedure employed to restore blood
flow to the heart. There are several procedures that may fall under this term.
Angioplasty includes procedures done without open surgery by accessing arteries
through the skin such as percutaneous transluminal coronary angioplasty (PTCA) and
arterial stenting. Additionally, coronary artery bypass (CABG) is a surgical procedure to
restore blood flow to the heart, falling under the revascularization term (Thygesen,
Alpert & Harvey 2007).
Cerebral Vascular Accident
Cerebral vascular accident (CVA), which is also referred to as a stroke, is a
condition that occurs when blood flow to the brain is obstructed and the brain is without
enough oxygen resulting in death of brain cells. There are 2 categories of stroke based
on etiological classifications of CVA, including ischemic and hemorrhagic strokes
(Benjamin et al., 2018; Speranza et al., 2000).
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Acute Ischemic Stroke
Acute Ischemic Stroke (AIS) is caused from narrowing or obstruction of blood
flow from atherosclerosis or an obstruction caused from a blood clot to the brain. It may
be transient as from a spasm or a clot that breaks free or minimal blood flow resulting in
hypoxia to the brain tissue usually without permanent damage; this is referred to as a
transient ischemic accident (TIA) (Benjamin et al., 2018; Kidwell & Warach, 2003;
NIHLBI, 2018).
Hemorrhagic Stroke
Hemorrhagic stroke is caused from bleeding in the brain that may cause
pressure and/or loss of blood flow to the brain, resulting in damage or death to brain
cells (NIHLBI, 2018).
Diabetes
Diabetes Mellitus, commonly known simply as diabetes, is a disease in which the
body’s ability to produce or respond to the hormone insulin is impaired, resulting in
abnormal metabolism of carbohydrates and elevated levels of glucose in the blood and
urine (Shoback & Gardner, 2011). It is considered a chronic metabolic disorder in which
the blood glucose is higher than the acceptable rages of 80-130 mg/dL. This
hyperglycemic state is a result of pancreas inability to control blood glucose levels.
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Type I Diabetes
Type I diabetes is the result of ineffective secretion of insulin by the pancreas,
with about 5-10% of all diabetics being type I (American Diabetes Association (ADA),
2018). Treatment includes daily administration of insulin.
Type II Diabetes
Type II diabetes is a failure of the pancreas to compensate for a resistance of the
insulin by the cells resulting in hyperglycemia. Diabetes affects more than 30 million
people in the United States, and approximately 90% of all cases are classified as Type
II (ADA, 2010).
Gestational Diabetes
Gestational diabetes is often temporary and occurs during pregnancy. With this
condition, the body is unable to maintain blood glucose levels within an acceptable
range. Persons having gestational diabetes have an increased risk of developing Type
II diabetes later in life (ADA, 2010; International Diabetes Foundation (IDF), 2018).
Depressive Symptoms
Symptoms of depression vary, but include loss of interest or pleasure, loss of
energy, fatigue, sleep problems, and changes in appetite. Depressive symptoms have
been linked to physiological changes such as increased inflammatory markers and is
therefore relevant to this study (Dannehl et al., 2014). Sometimes, symptoms that look
like depression are not really depression. Depressive symptoms range in seriousness
from mild, temporary episodes of sadness to severe, persistent depression. Clinical
depression is the more-severe form of depression, also known as major depression or
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major depressive disorder. Clinical depression is a treatable serious medical illness
according to the American Psychiatric Association (APA, 2015). This paper includes
persons with depressive symptoms, rather than a diagnosis of clinical depression.
InInterleukin-6 (IL-6)
Interleukin-6 is a measure of inflammation that has an expected value in the
general population of approximately 1-5 pg/ml. Secretion of IL-6 occurs as an acute
phase inflammatory response and plays a role in the process that leads to
atherosclerosis. IL-6 triggers the liver to produce the inflammatory marker C-reactive
protein (CRP) (Yudkin, Kumari, Humphries & Mohamed, 2000).
C-reactive Protein (CRP)
C-reactive protein is produced in the liver and adipocytes and is a part of the
acute phase inflammatory response (Martinez & Gonzalez- Juanatey, 2009). CRP is a
non-specific indicator of elevated inflammation that may occur secondary to stress,
infection, cancer, CVD, rheumatoid arthritis, and trauma (Yudkin, Kumari, Humphries &
Mohamed, 2000).
Highly Sensitive C-Reactive Protein (hsCRP)
Similar to CRP, hsCRP measures more specifically blood vessel CRP and is a
more specific measure with respect to risk of atherosclerosis. Current recommendations
for evaluating cardiovascular risks suggest the use of hsCRP. However, this
assessment may not be cost effective as a high level of accuracy requires multiple
laboratory measurements, 2 weeks apart, and with the average of the readings used to
estimate potential cardiac risk (CDC, 2018).
15

Quality of Sleep (Insomnia)
Sleep is the natural periodic suspension of consciousness during which the
powers of the body are restored (Harvey Stinson, Whitaker Moskoviz & Virk, 2008).
Insomnia refers to habitual sleeplessness or inability to sleep. Quality of sleep is
measured as insomnia, assessed as the ability to fall asleep or sleep latency, duration
of sleep and functional ability upon awakening. Quality of sleep has been linked to work
related injuries and errors, perceived quality of life, as well as physical illness including
increased inflammatory markers, diabetes, and cardiovascular disease. Research has
suggested that sleep of less than six-hours or poor quality of sleep (sleep apnea, for
example), increases risk for experiencing a cardiac event (Barger et al., 2017).
Traditional Risk Factors for CVD
A risk factor refers to something that increases health risk or susceptibility.
Below are definitions of several conditions that have been accepted as traditional risk
factors for CVD (Goff et al., 2014; Lin et al.,2018)
Hypertension
Hypertension refers to abnormally high arterial blood pressure that is usually
indicated by an adult systolic blood pressure of 120 mm Hg or greater or diastolic blood
pressure of 80 mmHg or greater (James et al., 2014; Whelton et al., 2017). Systolic
blood pressure represents the pressure exerted against arterial walls with each
heartbeat. This is the upper number on the blood pressure reading. The newest
guidelines recommend systolic blood pressure to be < 120 mm Hg. Diastolic blood
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pressure, the lower number of the reading, represents the pressure exerted against the
arterial walls between heartbeats. Consistent readings over guideline-specific
recommended levels are consistent with a diagnosis of hypertension (Whelton et al.,
2017).
Metabolic Syndrome
Metabolic syndrome is a cluster of conditions which include elevated blood
pressure, high blood sugar, excess body fat around the waist, low HDL (i.e. good
cholesterol) and high triglyceride levels. The higher number of these factors and having
at least 3 of the factors (definition of metabolic syndrome) increases future risk of CVD
(Zimmet, Alberti & Shaw, 2005).
Body Mass Index
Body mass index (BMI) is a person’s weight in kilograms divided by the square of
height in meters (kg/m2). A BMI greater than 25 indicates overweight; greater than 30 is
classified as obese (WHO, 2014).
Central Obesity or Abdominal Obesity
Central obesity is defined as excessive adipose in the abdominal area and is an
independent predictor of CVD. Measures in women greater than 89 centimeters and
men greater than 102 centimeters portend higher risk for CVD (Canoy et al., 2013).
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Dyslipidemia
Elevation of plasma cholesterol and triglycerides (TG) and low High-Density
lipoprotein (HDL) cholesterol levels are defined as dyslipidemia, and contribute to the
development of atherosclerosis (Bear, 2017). Although low HDL levels predict
cardiovascular risk in the overall population, the increased risk may be caused by other
factors, such as accompanying lipid and metabolic abnormalities, rather than the HDL
level itself. Etiology for dyslipidemia can be primary (genetic), or secondary and caused
by poor lifestyle or dietary practice, as well as some disease conditions (Goff et al.,
2014).
Triglycerides (TRIG)
Triglycerides carry unused fat cells to be stored and used for energy later.
Elevated triglycerides have long been considered a risk factor for CVD, and optimal
levels are less than 150 mg/dL (Baer, 2017; Goff et al., 2014). Elevated triglycerides in
diabetes increases the risk of CVD (Goff et al., 2014).
High Density Lipoprotein (HDL)
Low, serum HDL cholesterol is strongly associated with risk factors for CVD.
This cholesterol is often referred to as the “good” cholesterol as it works to transport fat
out of the arteries. Anti-inflammatory and antioxidant effects of high HDL levels reduce
endothelial damage and are favorable in preventing CVD (Goff et al., 2014).
Recommended values for women are greater than 55mg/dL and men greater than
45mg/dL (CDC, 2017; Smith et al., 2017).
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Low density Lipoprotein (LDL)
Low-density lipoprotein is often referred to as the bad cholesterol. Although not
listed as a component of the metabolic syndrome, elevated LDL plays a key role in the
development of atherosclerosis and is strongly associated with CVD. Recommended
levels for LDL are less than 130 mg/dL, however, more recent guidelines are
emphasizing lower numbers (<100 mg/dL). These values vary among agencies with
newer guidelines recommending target values based on risk analysis and comorbidities
(Baer, 2017; Pallazola et al., 2018).
Significance to Nursing
In the campaign against CVD, primary prevention with early identification of
potential modifiable risk factors is key in planning interventions to reduce occurrence of
the disease. CVD has become our Nations’ costliest chronic disease and will continue
to be the most burdensome disease that Americans will face in the coming decades.
Thus, expenses associated with CVD are expected to soar in coming years. Therefore,
identifying the degree to which depressive symptoms, inflammation, and sleep quality
influence development of CVD may support changes in how routine screenings are
conducted to better inform and manage CVD risk. This study aimed to address the gap
in knowledge that exists for the optimal development of appropriate screenings and
preventative measures to prevent cardiovascular disease.
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CHAPTER TWO:
REVIEW OF LITERATURE
Scientific evidence supports a strong relationship between a person’s lifestyle
and risk for developing or dying from CVD. The World Health Organization (WHO)
estimates that over 75% of premature CVD is preventable and risk factor amelioration
can help reduce the growing CVD burden among both individuals and healthcare
providers (Curry et al., 2018; Roth et al., 2017). While a general estimation of the
relative risk for CVD can be approximated by counting the number of traditional risk
factors present in a patient, a more precise estimation of the absolute risk for a first
CVD event is desirable when making treatment recommendations for a specific
individual.
This chapter presents the supporting evidence on the effects of traditional risk
factors for CVD including; age, race, gender, obesity, smoking, diabetes, hypertension,
and hyperlipidemia and the risk for developing CVD including the occurrence of a major
adverse cardiac event (MACE). In addition, literature supporting evidence of interaction
with demographic variables, as well as evidence on the non-traditional and potentially
modifiable risk factors of depressive symptoms, inflammation, and sleep quality and
their relationship to risk for CVD are discussed.
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Traditional Risk Factors For CVD
Age Gender and Race as Risk For CVD
Age is an independent “non-modifiable” risk factor for CVD and confers
heightened risk until the approximate age of 70 years when the risks start to level off
(Dhingra & Vasan, 2012). Aging is associated with a decline in cellular regeneration,
respiratory capacity, skeletal muscle decline, reduction in hormones, and a weakened
and often chronically alarmed immune system (Barzilai, Huffman, Muzumdar, & Bartke,
2012). Aging increase ones’ risk for hypertension, visceral adiposity, insulin resistance,
and atherosclerosis, all considered risk factors for CVD (Lopez-Candales, HernandezBergos, Hernandez-Suarez & Harris, 2017; Mosca, Barrett-Connor & Wenger, 2011).
Previous literature has used the term “heart age” to distinguish from chronological age.
Heart age estimates a person’s age based on the presence of cardiac risk factors. For
example, a 45-year-old obese, diabetic individual with hyperlipidemia and hypertension
would be “older” in heart age than a 50-year-old non-smoker non-diabetic, who is
overweight by about 10 pounds, and with normal blood pressure and cholesterol levels
(Hirsch, Wits, Li, & Soliman, 2018; Yang et al., 2015). The CDC reports that the
average American male has a heart age nearly 8 years and women 5.4 years greater
than their true years of age (Hirsch et al., 2018; Yang et al., 2015). Chronological age is
not modifiable but reducing modifiable risk factors could lower an individual’s heart age.
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Prior to reaching age of 45-years, men have a higher rate of hypertension,
increased arterial stiffness and endothelial dysfunction and nearly double the risk for
CVD compared to women (Mosco, Barrett-Connor & Wenger, 2011; Benjamin et al.,
2018). Cardiovascular disease develops, on average, 7 to 10 years later in women than
in men (Maas & Appelman, 2010). As women start to age into the sixties, the rates start
to even out for women, and those with comorbidities may have a higher risk for CVD
than men (Benjamin et al., 2018; Mosco et al., 2011;). These differences could be
related to female hormones that reduce with age and then cease during menopause. It
has been thought that estrogen may have protective components. Rat studies have
found estrogen to have a significant effect in epithelial homeostasis, anti-fibrotic effects,
vasodilatation, and a reduction in oxidative stress, all factors directly related to the
development (or lack thereof) of atherosclerosis (Lorga et al., 2017). Additionally,
women who experience premature menopause, having lost the protection of estrogen
before the age of 40, have been found to have a shorter life (Rocca et al., 2012; Sabbag
et al., 2017).
Physiologically, women with CVD react differently and have poorer outcomes
then men. Women often present with atypical complaints when experiencing an MI and
have a higher risk of mortality (Sabbag et al., 2017). Symptoms do not always include
the crushing chest pain, shortness of breath easily recognized as a potential cardiac
event. Women complaints can be vague, including, fatigue, diaphoresis, and nausea
(Mehta et al., 2016; Sabbag et al., 2017). These presentations contribute to delay in
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medical evaluation and/or misdiagnoses, as women have been found to have higher
rates of Global Registry of Acute Coronary Events (GRACE) score ≥140 (19% vs 12%,
p = .007) (Sabbag et al., 2017). Moreover, revascularization procedures may be less
likely to be successful in women who may have less complete blockages (Merz &
Chang, 2016; Mehta et al., 2016). Additionally, revascularization procedures have
increased bleeding complications thought to be related to increased platelet aggregation
in women (Maas & Appelman, 2010; Mehta et al., 2016). These differences in
presentation with MACE place women at a higher risk for misdiagnosis, delay of
treatment, including invasive interventions, and death (Maas & Appelman, 2010; Mehta
et al., 2016; Merz & Chang, 2016).
Historically, CVD risk factors are seen disproportionately in racial and ethnic
populations (Kurian & Carderelli, 2007). An awareness of the disparities of CVD risk
factors by race and ethnicity may guide clinicians to develop culturally sensitive
educational, interventional and prevention programs aimed at risk factors prevalent
within these populations. Blacks have been considered at higher risk for CVD. An
analysis using subject data from both The Mediators of Atherosclerosis in South Asians
Living in America study and The Multi-Ethnic Study of Atherosclerosis study reported
Blacks to have more than double the risk for developing atherosclerotic CVD after all
adjustments, compared to whites, HR 2.23, 95% CI [1.51, 3.30] (Kullo et al., 2007; Rifai
et al., 2018). Hypertension, diabetes, obesity, and atherosclerosis have a higher
prevalence at an earlier age in the Black population (Carnethon et al, 2017). According
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to the American Heart Association (AHA), deaths rates for CVD are 270.6 per 100,000,
for Non-Hispanic White Males compared with, 356.7 for Non-Hispanic Black males and
183.8 for Non-Hispanic White females and 246.6 for Non-Hispanic Black females
(Benjamin et al., 2018). Cardiovascular related death rates are consistently higher
among Blacks.
Despite this increased rate of mortality in the Black population, Blacks have
paradoxically been found to have favorable lipid profiles in comparison to Whites.
Racial differences in lipoprotein levels have previously been reported in the Heart
SCORE study. For blacks compared to whites, the breakdown is as follows. Blacks
had higher HDL cholesterol levels compared to Whites. Both Black men and Black
women had fewer small dense LDL particles than their White counterparts (Aiyer, et al.,
2007; Kullo et al., 2007). Similar findings are reported by Gaillard and Osei, (2016), that
women with an elevated risk of obesity and many with prediabetes were analyzed for
racial differences. Blacks with prediabetes were more obese (BMI 38.8 + 6.7 kg/m2
than White 36.0 +5.4 kg/m2). Also, Blacks had lower triglycerides levels ( 84.4 +47.9
mg/dL) than Whites (125 +55.5 mg/dL). Moreover, this study reported higher HDL
cholesterol levels and higher small sized LDL cholesterol in Black women (Gaillard &
Osei, 2016).
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Diabetes as a Risk For CVD
Diabetes has long been considered a “cardiovascular risk equivalent” and people
with diabetes have 2 to 4 times increased risk of CVD morbidity and mortality than
individuals without diabetes (Bertoluci & Zorzanelli, 2017). Younger diabetics such as
men under the age of 35 years and women under 45 years without a raised LDL
cholesterol level (more than 100 mg/dL), normotensive with no past cardiac history or
obesity may not be at a greater risk. It was suggested in determining preventive
measures, that the need for statin medication should make use of a more individualized
approach (Bertoluci & Zorzanelli, 2017). The Cardiovascular Health study sought to
explore differences by gender and race in risk for CVD. Compared to non-diabetics, a
significant increased risk for CVD was established for Black, diabetic women HR 2.15,
95% CI [1.43, 3.23] and Black diabetic men HR 1.48, CI 95% CI [0.92, 2.39]. Interaction
between diabetes, gender, and CVD was not significant (Vimalananda et al., 2014).
Diabetes has been long linked to CVD. Among those with Type II diabetes, 75%
or greater of all hospitalizations and more than 50 % of deaths, are related to CVD
(Benjamin et al., 2018). Diabetics, especially persons with Type II tend to be more
overweight and have a more sedentary lifestyle in comparison to those without diabetes
(Dokken, 2008). However, not everyone with diabetes is the same and differences in
medical and family history, gender, race, and age influence risk. The AHA/ACC have
suggested that diabetics be stratified for risk based on presence of comorbidities (Goff
et al., 2014).
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The physiological changes associated with diabetes, elevated blood glucose, and
inflammatory responses place the diabetic individual at greater risk for atherosclerosis,
which is a major component to CVD. Vascular endothelium lines the entire circulatory
system and is responsible for maintaining blood vessel tone including vasodilation and
constricting, and prevents thrombogenesis and inflammation (Rajendran et al.,2013).
When blood sugars rise, the normal homeostasis and function of the endothelium is
altered, and an inflammatory response releasing free radicals leads to the oxidized LDL.
Diabetics often have an increased low-density lipoprotein (LDL) but smaller in size
(Dokken, 2008). The smaller LDL are more likely to become oxygenized. In the effort of
leukocytes and macrophages to destroy the oxidized LDL, foam cells occur and attach
to the vascular wall along with LDL cells that lead to atherosclerosis. The effected
endothelium is also responsible for platelet activation which is important in clot
formation. This alteration in the endothelium may lead to platelet aggregation
increasing the risk of blood clots forming (Dokken, 2008: Rajendran et al., 2013).
The prevalence of depression has been reported as two-fold in diabetics
compared to non-diabetics (Anderson, Freedland, Clouse, & Lustman, 2001; Badescu
et al., 2016). Furthermore, diabetics with depression have a much higher rate of
atherosclerosis and have been reported to have a 50% increased mortality rate, and
40% increased rate of CVD over those without depression (van Dooren et al., 2013).
These alarming findings support the concern for those with the combined effect of
having diabetes and depressive symptoms being at a greater risk for developing CVD.
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The connection between diabetes, hyperglycemia, and atherosclerosis is an
obvious risk for CVD. Maintaining glucose control through diet, exercise, and taking
medications as prescribed is imperative for a diabetic to limit these devastating effects.
Poor medication compliance in diabetes has been shown to increase mortality by 45%
and risk of a cardiac event by 41% (Kim et al., 2018).
Smoking as a Risk for CVD
Smoking is a modifiable independent risk factor for CVD. According to the
Surgeon General’s Report, smoking is a major cause of CVD and is responsible for one
in every five deaths (Benjamin et al., 2018). Those who smoke as few as five cigarettes
a day and nonsmokers, with exposure to secondhand smoke, experience an increased
risk for CVD compared to nonsmokers (Benjamin et al., 2018). Smoking has a profound
physiological effect and is estimated to shorten one’s life by 10 years (Jha et al., 2013;
McBride, 1992).
A brief explanation of the pathology of a cigarette will shed light on the effects of
smoking and the development of CVD. Upon inhaling a cigarette, the nicotine,
numerous chemicals and free radicals are not freely accepted, and an acute immune
response is activated. The resulting response results in the release of hormones
including adrenaline and noradrenaline (Powell, 1998). These hormones promote
vasoconstriction, as well as an increase in heart rate and blood pressure (Gordan,
Gwathmey & Xie, 2015; McBride, 1992). Simultaneously the immune response leads to
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build up of oxidized LDL and foam cells attaching to the endothelium wall (Al-Delaimy et
al., 2002; Messner & Bernhard, 2014; Morris et al., 2015). This inflammatory response
within the endothelium was also described as a response high glucose levels in
diabetics. The elevated heart rate and blood pressure increases oxygen demand.
However, the oxygen carrying erythrocytes have absorbed carbon monoxide (CO)
inhaled from the cigarette (Powell, 1998). The CO binds with the oxygen, resulting in
the erythrocytes carrying carboxyhemoglobin and unable to transport the needed
oxygen (Powell, 1998). To compensate for the need of oxygen, the body releases
additional erythrocytes to transport the oxygen. The excess of erythrocytes referred to
as erythrocytosis increases the viscosity of the blood which may slow movement
through veins and arteries and may impede capillary flow completely (Sopori, 2002).
Additionally, the immune system also initiates platelet aggregation increasing the risk of
clot formation (Sopori, 2002).
A meta-analysis combining 25 separate cohort studies of the CHANCES
consortium evaluated risk for CVD mortality and events in relation to smoking (Mons et
al., 2015). Cox proportional hazard regression indicated that the risk was elevated for
current smokers HR 2.07, 95% CI [1.82, 2.36] and former smokers HR 1.37, 95% CI
[1.25,1.49]. Similarly, risk for cardiac events for current smokers HR 1.98, 95% CI [1.75,
2.25] and for former smokers HR 1.18, 95% CI [1.06, 1.32] were elevated (Mons et al.,
2015).
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Smokers were reported to lose 10 years off their lifespan however, if they quit
smoking prior to the age of 34 years, recalculated survival analysis indicated life
expectancy nearly identical to a non-smoker, gaining back 9 years of life. If one does
not stop smoking until after the age of 34 years, they will still regain 4-6 years of life
(Jha et al., 2013). Thus, it is never too late to quit smoking. Smoking cessation has
significant benefits including a reported 36% reduction in CVD mortality seen over a 2year period for those who quit smoking after having an MI (Rigotti & Clair, 2013). Actual
benefits of quitting will be affected by how much one smoked on average per day and
for how many years. After quitting smoking, risk for CVD drops drastically for the first 4
years, and then slows beyond that. (Bullen, 2014; Dresler et al., 2006).
In summary smoking has a profound effect on endothelial function. The
constricted vasculature is lined with epithelium that has now has waste products
attached to its walls, impeding blood flow, and a dysfunctional ability to cause
vasoconstriction or dilatation (McBride, 1992). The blood is now thicker and sticky with
an excess of platelets and erythrocytes and reduced oxygen (Powell, 1998). One can
visualize how 20-40 cigarettes a day can significantly add to atherosclerosis, blood clots
or complete occlusions, and as a causal basis for ischemic heart disease.
Hypertension as a Risk for CVD
Hypertension is quantitatively the most important traditional risk factor for
premature CVD; it is more common than cigarette smoking, dyslipidemia, and diabetes
29

and accounts for an estimated 47% of all ischemic heart disease events globally (Wong et al.,
2012). Among a large sample of subjects with a diagnosis of hypertension and either high

Framingham Risk Score (FRS) (>20%), 23% or with prior CVD 32% ; almost two-thirds
of hypertensive males 61% were found to be in the high-risk CVD groups compared to
49% of the females (p < 0.001) (Wong et al., 2012). This study also reported that
Hispanics with a diagnosis of hypertension were less likely to be at higher risk than
other ethnicities (p < 0.05) (Wong et al., 2012).
Racial differences in blood pressure have long been reported with Blacks having
a higher prevalence and incidence of hypertension, as documented by AHA statistics
obtained from 2009-2012. Indeed, an alarming 44.9% of adult Black men and 46.1%
Black women have been diagnosed with hypertension compared to an overall rate of
32.6% for the entire US adult population (Mozaffarian et al., 2016). In contrast, The
Systolic Blood Pressure Intervention Trial (SPRINT) looked at treatment modalities for
hypertension as well as racial differences. Systolic BPs in this study were not
significantly different among the different racial groups of Non-Hispanic White, NonHispanic Black and Hispanics (Still et al., 2018). This result varies from that reported by
AHA that Non-Hispanic Black have more hypertension and death rates more than 30%
higher than the general population (Still et al., 2018). In a study of high-risk veterans
that included 23,955 men and 1,010 women and assessment of three risk factors that
predispose to CVD (diabetes, hypertension, and hyperlipidemia), average BP was
reported higher among Blacks comparative to whites. Black female veterans after age
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adjustment had estimated mean systolic BPs of 136.3 mmHg as compared to 133.5
mmHg among white female veterans (p < .01). Mean diastolic BPs for black females
were 82.4 mmHg versus 78.9 mmHg for white females (p < 0.01) (Goldstein et al.
2014). Large variations between studies was noted. It is necessary to continue
monitoring for age, gender and racial differences. When evaluating population-wide
blood pressure variation, it is important to include treatment modalities. In addition,
future studies using age-adjusted models, models assessing relative risks compared to
others of same age, and models including thorough assessments of target organ
damage and ambulatory 24-hour blood pressure are needed to tighten the knowledge
gap in elucidating differences among different ages, races, and gender.
Obesity as a Risk for CVD
As the prevalence of obesity continues to rise in the United States, the rate of
CVD and associated complications will also increase. The obesity epidemic has the
potential to reduce further gains in the US life expectancy, largely through an adverse
effect on CVD mortality (Benjamin et al., 2018). The CVD risks associated with obesity
are often assessed using the body mass index and central or abdominal obesity.
Body Mass Index as a Risk for CVD
Body Mass Index (BMI) is a measure of not only height and weight but also
overall body mass. BMI is a preferred measure when looking at risk factors as it
correlates with overall body fat, which is often linked with risk for heart disease (CDC,
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2013). The calculation is based on a formula weight/height2 (kg/m2). A healthy BMI is
(25 kg/m2), increasing BMI is considered a key component to the metabolic syndrome
(Zimmet, Alberti & Shaw, 2005). A number of studies have documented the association
between obesity and cardiovascular disease (CVD) risk factors (Freedman, Khan,
Serdula, Galuska, & Dietz, 2002; Gregg et al., 2005).
Central Obesity as a Risk for CVD
Central obesity is when body fat is disproportionately distributed in the abdominal
area, with some describing it as having a pear shape. Central obesity has been found to
be more predictive of mortality than an elevated BMI (Coutinho et al., 2013). For
example, men with a normal BMI (this study used < 22 kg/m2 as normal), but with
central obesity compared to men with an elevated BMI and no central obesity were at
twice the risk for mortality, HR 2.42, 95% CI, [1.30, 4.53]. This study had comparable
results among women, with central obesity being the most predictive factor for mortality
(Sahakyan et al., 2015).
Lipid Levels and Risk for CVD
Dyslipidemia is a term that refers to elevation of plasma cholesterol, triglycerides
(TRIGs), or both, or high LDL cholesterol or a low HDL cholesterol level that contributes
to the development of atherosclerosis. Dyslipidemia is recognized as a prominent risk
factor for CVD (Miller, 2009). Current guidelines focus on lowering LDL with a statin in
both primary and secondary prevention, and a consensus statement by Pallazola et al.
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(2018) reports discordance between established guidelines and global practices. The
authors who reviewed five guidelines reported differences among major guideline
committees and recommended addressing beyond risk estimation and aggressive
management of moderate- to high-risk patients and the need for a unified guideline
(Pallazola et al., 2018). Therefore, understanding the association between the levels of
these lipids and CVD risks are important.
Triglycerides (TRIG) as Risk for CVD
Despite three decades of research, the controversy regarding the relationship
between triglycerides and risk of CVD persists. Although, earlier cohort studies reported
a univariate association between TRIG and CVD, this association was no longer
statistically significant after adjustment for either total cholesterol (TC) or LDL
cholesterol (Di Angelantonio et al., 2009). Cardiovascular risk was evaluated in a large
cohort study of American Indians (N= 3216) over 17 years. This study reported that
elevated TRIG in combination with low HDL increased the risk for developing CVD by
1.32-fold 95% CI [1.06. 1.64], and having diabetes increased this risk by 1.54% (Lee et
al., 2017). After adjusting for covariates, a different study compared those with TRIG
levels less than 100 mg/dL to those with greater than 500 mg/dL, with those with greater
than 500 mg/dL being at greater than 60% higher risk of death over 22-years (Klempfer
et al., 2016).
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The Framingham Heart Study found that both genders were at a significantly
greater risk for developing CVD if there LDL cholesterol level was greater than
160 mg/dL compared to those with an LDL less than 130 mg/dL, HR 1.74, 95% CI
[1.36,2.24] for men and HR 1.68, 95% CI [1.17, 2.40] for women (Wilson et al., 1998).
Similarly, in the Atherosclerosis Risk in Communities (ARIC) study, with a study
population of over 12,000 middle aged men and women, the risk of coronary heart
disease was significantly related to LDL levels. In fully adjusted models including age
race smoking systolic blood pressure and diabetes the HR for elevated LDL for women
was significant for men (HR 1.43) and women (HR 1.24) without any previous history of
CVD (Sharrett et al., 2001). Thus, elevated LDL is an indication for aggressive
treatment for primary prevention of CVD.
High Density Lipoprotein (HDL) as Risk for CVD
Desired levels of HDL cholesterol in men are >40 mg/dL and in women are >50
mg/dL (CDC, 2017). HDL, often referred to as the good cholesterol, is considered an
independent risk (protective) factor for CVD (Toth, 2004). It is responsible for
transporting excess fat and cholesterol and has anti-inflammatory properties reducing
endothelial cell changes and decreases platelet aggregation. Low levels of high-density
lipoprotein cholesterol (HDL; <40 mg/dL) are associated with increased risk of
cardiovascular events (Toth, 2004). The cardioprotective functions of HDL include
antioxidative, anti-inflammatory, anti-apoptotic, anti-thrombotic, vasodilatory, antiinfectious and antidiabetic activities (Hagstrom et al., 2016). The TRILOGY Acute
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Coronary Syndrome trial evaluated HDL level as a dichotomous variable-very low
(<30 mg/dL) vs, higher (≥30 mg/dL) and reported similar rate for a composite endpoint
with essentially no risk difference between groups HR 1.13, 95% CI [0.95, 1.34] for MI
and stroke. However, risks for cardiovascular death HR 1.42, 95% CI [1.13, 1.78] and
all-cause death HR 1.36, 95% CI [1.11, 1.67] were higher in patients with very low
baseline HDL (Hagstrom et al., 2016).

Low-Density Lipoprotein (LDL) as Risk for CVD
Elevated LDL is an indication for primary prevention of CVD. The rationale for
activities focused on LDL reduction is based upon epidemiologic data documenting a
continuous, positive, graded relationship between LDL concentration and CVD events
and mortality (Leef, Bluementhel, & Martin, 2018; Wallis et al. 2000). Earlier evidence
from The Framingham Heart Study demonstrated that men and women were >1.5 times
more likely to develop clinically significant coronary artery disease if their LDL was
>160 mg/dL compared to a reference population with LDL <130 mg/dL (Wilson et al.,
1998). Similarly, in the Atherosclerosis Risk in Communities (ARIC) study, the risk of an
incident coronary heart disease event was elevated by approximately 40% for every
39 mg/dL incremental increase in LDL (Sharrett et al., 2001).
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Non-Traditional Risks For CVD
Depressive symptoms as a Risk for CVD
Major depression and depressive symptoms are commonly underdiagnosed and
undertreated in patients with CVD (Celano & Huffman, 2011). Studies have found
depression and its associated symptoms to be major risk factors for both the
development of CVD and increased mortality post myocardial infarction (Silverman,
Herzog, & Silverman, 2018). Furthermore when cardiac disease and major depression
present together, the prognosis is worse (Celano & Huffman, 2011; Mehta et al., 2016)
The Enhancing Recovery in Coronary Heart Disease (ENRICHD) trial among
patients who had recently suffered a myocardial infarction (MI), reported a diagnosis of
depressive symptoms in 74% of the cohort (Carney et al., 2004). Depressive symptoms
were associated with an included increased risk of CVD mortality HR of 1.57, 95% CI
[1.06, 2.33], p=0.03 in a cross-sectional survey of 1,569 subjects (Ivanovs et al., 2018).
Likewise, depressive symptoms evaluated among 1,928 persons with known coronary
artery disease had an alarming effect. Depressive symptoms were measured by the
Depression Scale (DEPS), a 10 item self-rating depression scale. Those in the highest
quartile of depression at baseline were 4 times at risk for cardiac related death
compared to those in the lowest group, HR 4.0, 95% CI [1.5, 10.5], p< 0.0001. The third
highest quartile was also significantly elevated compared to the lowest HR 2.3, 95% CI
[1.3, 4.1], p <0.05. This study concluded that depression had a significant effect on
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cardiac related deaths, but not deaths unrelated to cardiac disease (Lahtind et al.,
2018).
Findings from the Maine-Syracuse Study, (N=970) persons were measured for
depressive symptoms using both the CES-D and the Zung self-rating depression scale
(Crichton, Elias, & Robbins, 2016). Significant findings included an association between
risk for metabolic syndrome and CES-D, OR 1.79; p=1.79 and the Zung depression
score OR 1.71; p<0.01. Alarming was the use of antidepressants which seemed to
increase the risk of Met S compared to persons not taking antidepressants OR 2.22;
p<0.001 (Crichton et al., 2016). On the other hand, a smaller study conducted in
Singapore included adults aged 21-50 years with major depression presently on
antidepressant medications compared to non-depressed controls and non-medicated
persons with depression (Ho et al., 2018). Persons taking antidepressants had
significantly higher elevated blood pressure, elevated IL-6 and lower HDL, when
compared to the non-depressed control group. Researchers suggested screening for
depression severity be added to the Framingham equation so not to miss major risks for
developing CVD (Ho et al., 2018). This study did not identify a benefit to medications
nor identify the medications used to treat depression. They reported an interaction
between TRIG and severity of depression.
Although evidence has strongly indicated that depression and/or depressive
symptoms may significantly affect the risk of CVD, the effect may differ within different
populations. Rates of depression are nearly twice as high in women compared to men
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(Vaccarino & Bremner, 2016; WHO, 2017, CDC, 2012). Women diagnosed with
depression have a higher incidence of cardiovascular disease (Lichtman et al., 2008;
Mehta et al., 2016), and poorer outcomes post cardiac event, including higher rates of
death over those without depressive symptoms (Celano & Huffman, 2011; Mehta et al.,
2016; Rutledge et al., 2006). A large study, (N=13,000) examined participants over a 2year span for effects of depression, measured with Beck’s Depression Inventory, and
the risk for CVD. Those with depression were at 2 times higher risk for CVD; Men
(n=6392), OR 2.14, CI 1.78, 2.56]; and women, (n=7153), OR 2.03, 95% CI [1.70, 2.43]
(Piwonski, Piwonska, & Sygnowska, 2014).
Depression may affect different age groups differently. A Swedish study included
people aged 25 to 64 with the diagnosis of depression, and those 25 to 79 hospitalized
with nonfatal CVD (n = 1,767). The results indicated a strong association between
depression and CVD, and those diagnosed with depression under the age of 40 were at
twice the risk for CVD compared to the older ages RR 2.17, 95% [CI 1.5, 3.03]. Those
over the age of 70 years at the onset of depressive symptoms experienced no
significant risk for CVD (Sundquist, Li, Johansson, & Sundquist, 2005).
Collectively, the evidence indicates that depression and/or depressive symptoms
are a strong risk factors for CVD across various populations. Depression can lead to
unhealthy eating habits, poor sleep quality, a decrease in physical activity, and elevated
inflammation, all of which may lead to atherosclerosis (Stapelberg, Neumann, Shum,
McConnell, & Hamilton-Craig, 2011).
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Inflammation and Inflammatory Markers as Risk for CVD
Aging is associated with dysregulated immune and inflammatory responses.
Inflammation has been suggested to be one of the mechanisms underlying the
pathogenesis of several age-associated diseases disease including CVD (Libby, 2006)
and obesity and diabetes (Shoelson, Herrero, & Naaz, 2007).
Age related effects of inflammation include overall low-grade inflammation due to
cumulative tendencies. The stress that an individual has experienced throughout life
builds up and scars generating more inflammation. It is thought that healthy persons
may experience some of these aging changes as early as age 55 years (LopezCandales, Hernandez-Bergos, Hernandez-Suarez & Harris, 2017). Chronic
inflammation increases the risk for developing atherosclerosis, Alzheimer’s disease, and
insulin resistance (Barzilai, Huffman, Muzumdar, & Bartke, 2012).
Gender differences were reported in a small pilot study seeking to evaluate
gender differences in persons experiencing an acute myocardial infarction (AMI).
Results found levels of IL-6 to be elevated significantly in men versus females. Patients
were tested after hospitalization on day 3 post diagnosis of a NSTEMI and on day 5
post diagnosis of a STEMI. This study concluded a significant association between
inflammatory markers IL-6 and CRP in men more so than women with a MI (Siennicka
et al., 2018). The English Longitudinal Study of Ageing Study sought to evaluate the
combined effect of both inflammation and depression. In men, the effect was highly
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significant HR 3.89, 95% CI [2.04, 7.44]; p= 0.001 while in women a significant risk was
not reported. Men with elevated inflammation and normal levels of symptoms of
depression had elevated risk HR 2.43, 95% CI [1.59, 3.71]; p<0.001, whereas women
were not at significantly higher risk HR 0.92, 96% CI [0.59, 1.44]; p=0.715 (Lawes,
Demakakos, Steptoe, Lewis, & Carvalho, 2018).
The inflammatory processes described within effects of diabetes and smoking
illustrate some of the physiological changes that occur when exposed to an
inflammatory process. Normal inflammatory marker levels can be valuable in ruling out
disease conditions. Conversely, an elevated inflammatory marker may indicate a higher
probability of a condition being present or identifies the risk of being exposed to a
specific disease condition. Various measures of inflammatory markers have been
associated with higher risk of CVD (i.e. High sensitive C-reactive protein (hsCRP) and
IL-6) being the most commonly reported (Chuang, Chih-Hung & Fang, 2014).
Inflammatory markers such as IL-6 and CRP have both been predictive of
cardiac events. A prospective study over a six-year span followed over 900 male
physician participants with no history of CVD. At the end of the study, 202 participants
had experienced a myocardial infarction. Participants with IL-6 levels in the highest
quartile had a 38% higher risk compared to those in the lower range, with a relative
index of 2.3 times that of those in the lower quartile (Ridker, Rifaai, Stampfer &
Hennekens, 2000). Similar findings were seen in a Japanese study (N =121) in which
fifty percent of the participants experienced a new cardiac event within a three-year
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span. In this study, baseline IL-6 was found to be an independent predictor of MACE
with those in the highest quartile of IL-6 compared to those in the lowest quartile HR
3.33, 95% CI [1.63, 6.81] (Nishida et al., 2011). In this study after controlling for other
variables, IL-6 was the better predictor of CVD, as hsCRP was not predictive (Nishida et
al., 2011). Likewise, hsCRP and IL-6 were associated with CVD mortality and all-cause
mortality, HR 2.15 and HR 2.11 respectively in the STABILITY study. However, after
adjustments Il-6 remained the stronger predictor and hsCRP was no longer significant
(Held et al., 2017).
IL-6 has also been shown to be an independent predictor of CVD mortality after
MI. Specifically, when IL-6 was measured 6 hours after first symptoms of an MI and
patients were followed for 3 years to monitor mortality, those who had the highest
reading of IL-6 had the highest mortality and cardiac events, as indicated by Kaplan–
Meier plots (X2 14.13, p=0.0002) (Fan et al., 2011). This study recommended the
possibility of treating with inflammation with medications such as tocilizumab to reduce
the levels of IL-6 and to prevent atherosclerosis (Fan et al., 2011).
Evidence in recent years has demonstrated an association between elevated
inflammatory markers and increased risk for CVD and mortality (Held et al., 2017;
Nishida et al., 2011). Although the etiology of the inflammation may vary greatly, early
detection and identification may allow for treatment or interventions to reduce the
inflammation and thus potentially reduce risk of CVD.
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Strong relationships seem prevalent among depression, CVD, and inflammation.
Studies are mixed whether the relationships may be bidirectional. What comes first
inflammation or depression, CVD, or depression? A meta-analysis by Howren, Lamkin
and Suls (2009) suggested a positive association between depression and inflammation
among patients with cardiac disease. Elevated inflammatory markers have been shown
to be predictors of heart disease and have been linked to both CVD and depression
(Danesh, et al., 2004; Dixon et al. 2008; Empana et al., 2005; Manev et al., 2008;
Taylor, Aizenstein & Alexopoulos, 2013). A direct causal path from depression and
CVD has been suggested after adjusting for inflammatory markers (Empana et al.,
2005). A Malaysian study conducted among more than 400 persons noted bidirectional
effects between depression and CVD. Depressive symptoms increased inflammatory
markers leading to CVD, and an increased rate of CVD led to increased depression
(Tajfard et al., 2014).
The joint effect of depression and/or depressive symptoms, inflammation and
CVD have been reported in a number of studies. Men with both elevated C-Reactive
Protein (CRP) with the presence of depressive symptoms had an increased risk of CVD
related death HR 3.89, 95% CI [2.04, 7.44] (Lawes et al., 2018), whereas those with
normal CRP and depressive symptoms had no significant increased risk for CVD (HR
1.50, 95% CI [0.63, 3.6]; p= 3.61 (Lawes et al., 2018). An Iranian study conducted on
more than 462 persons also noted significant associations between depressive
symptoms and inflammatory markers IL-6, IL-8 (p <0.05) and depressive symptoms.
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These researchers concluded an interaction between depressive symptoms and CVD
that was probably mediated by the inflammatory processes (Tajfard et al., 2014).
Sleep Quality/ Insomnia as Risk for CVD
Previous research suggests that poor sleep quality, sleep disorders, and
insomnia increase the risk for CVD (Covassin & Singh, 2016). Key search words
included sleep, insomnia, sleep disorders, hypertension, diabetes, obesity, heart
disease, cholesterol, age, race, and gender Sleep is a potentially modifiable risk factor
in the fight against CVD. Sleep quality has been associated with increased risk of many
health conditions including CVD (Covassin & Singh, 2016). Although, sleep quality
may vary among individuals, the duration of sleep, time taken to fall asleep, one’s ability
to stay asleep and daytime sleepiness or inability to stay awake have been significantly
associated with the risk for CVD (Hoevenaar-Blom, Spijkerman, Kromhout, van den
Berg, & Verschuren, 2011). Therefore, a review of current studies on sleep and CVD
risk was conducted to shed light on the connection.
Changes in sleep patterns are common complaints in older people. Age related
differences include sleep that is less consolidated, with increased interruptions. Change
in sleep cycles including the Rapid eye movement (REM) cycle occurs earlier in sleep
cycles compared to younger persons. There is evidence supporting that for every
decade of an age they lose about 10-minutes of sleep. (Edwards, O’Driscoll, Ali, Jordan,
Trinder & Malhotra, 2010). Aging is characterized by changes in both sleep and
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circadian rhythms. Many older adults find their circadian rhythm has been moved
forward. Changes in body temperature and hormonal secretions regulated by the
circadian rhythm such as melatonin and morning rise of cortisol seems to come at an
earlier time. Older persons tend to rise earlier than their younger counterparts (Dijk et
al., 2000). Although occasional sleep complaints may not be associated with age, older
adults experience chronic sleep difficulties more often than by younger adults. A similar
poll of 1500 older Americans (aged 55+) found that 67% reported trouble sleeping and
that only one in eight had discussed these problems with their physicians (Lamberg,
2003). It would be fair to say that older persons are at a greater risk for health-related
problems for which may affect sleep (Edwards et al., 2010)
Sleep complaints may also vary within different races. Results from the MultiEthnic Study of Atherosclerosis (MESA) have Black men sleeping the shortest duration,
and White women the longest. Black men complain of daytime sleepiness the most.
None of the differences however were significant (Chen et al., 2015)
Cardiovascular disease may be affected by sleep quality in a number of ways. A
study with over 20,000 participants found those with shortened sleep of less than six
hours had a slightly higher risk of developing coronary vascular disease after controlling
for relevant lifestyle factors such as smoking, exercise, and alcohol consumption HR
1.23, 95% CI [1.04, 1.45]. Also, this study reported that the risk for CVD decreased with
longer sleep, eight hours HR 0.87, 95% CI [0.74, 1.02] and for those with more than
nine hours of sleep HR 0.77, 95% CI [0.58,1.02] (Hoevenaar-Blom, Spijkerman,
Kromhout, van den Berg, & Verschuren, 2011). Sleep quality measured with a single
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question (Do you usually rise feeling rested?) combined with short duration of sleep
demonstrated a significant increase in CVD risk for CVD HR 1.79, 95% CI [1.24, 2.58];
p<.05 (Hoevenaar-Blom et al., 2011).
The above evidence was supported in The Women’s Health Initiative
Observational Study Participants (N=86,329) of female participants, aged 50 to 79. This
study results found those with elevated insomnia scores had and elevated risk for CVD
(38%). Upon evaluating duration those with less than five hours and more than ten
hours of sleep to have an increased risk for CVD with age and race adjusted models
however in fully adjusted models, no statistical significance for less than 5 hours of
sleep was appreciated (Sands-Lincoln et al., 2013). However, upon testing for
interaction, those with both insomnia symptoms and longer sleep duration, slept greater
than 10 hours had nearly double the risk for CVD, HR 1.93, 95% CI [1.06, 3.51]; p<0.1
(Sands-Lincoln et al., 2012). These results support the thought that quality of sleep
influences the risk for CVD, increasingly so when duration and insomnia symptoms of
bother, are both present.
Sleep quality can be affected by depression and or depressive symptoms.
Persons with poor sleep quality were nearly 10 times more likely to have depression
compared to those without symptoms in a community-based sample of 772 participants
(Taylor, Lichstein, Durrence, Reidel & Bush, 2005). Sleep quality, measured by
Pittsburgh Sleep Quality Index (PSQI), and depression and anxiety, measured by the
Hospital Anxiety and Depression Scale (HADS) were measured on patients hospitalized
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with a variety of cardiovascular related diseased (N=1071). Among patients hospitalized
with a cardiac event, 43% percent of patients reported poor sleep quality. Sleep quality
after adjustments for covariates was a significant risk factor for depression in this group
HR 1.09, 95% CI [1.03, 1.15]; p=0.002 (Matsuda et al, 2017). Additionally, a test for
interaction by gender, sleep and depression revealed differences among gender,
women with poor sleep quality where at a much higher risk for depression compared to
men; women OR 1.34, 95% CI [1.22, 1.48]; p<0.001, Men OR 1.17, 95% CI [1.12, 1.23];
p=0.017 interaction (p=0.008) (Matsuda et al., 2017).
There have been significant associations reported between increased
inflammatory markers and sleep quality. Those with interrupted sleep or sleep of
extremely short or long duration have been associated with increased levels of CRP
and IL-6 (Mullington, Simpson Meier-Ewert & Haak, 2010). Shift workers, those with
circadian rhythm disorders, and those with reported shortened sleep or poor sleep
quality, have also been identified as having elevated markers (Kudielka, Buchtal, Uhde
& Wust, 2007; Patel et al., 2009). Furthermore, insomnia appears to be associated with
hypercortisolemia and a daytime shift of IL-6 and TNFα secretory patterns, conditions
that may lead to multiple health problems including visceral obesity, insulin resistance,
hypertension, and osteoporosis that, in turn, may affect longevity (Vgontzas et
al., 2003). Smoking has been associated with sleep quality. Common reported
difficulties in smokers include, sleep latency, duration with frequent awakening daytime
sleepiness (Wetter & Young, 1994).
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Summary
Current evidence suggests the modifiable risk factors depression and or
depressive symptoms, inflammation, and quality of sleep, play a role in the development
of CVD. Studies collectively have found depression and or depressive symptoms to
increase one’s risk for CVD by approximately 1.5 times or more. The exact link as to
how depression would increase a person’s risk is not fully known and may be the effect
of many components. Depression and or depressive symptoms effects an individuals’
diet, activity, sleep patterns and may also result in an inflammatory response. The link
from inflammation and CVD is strong and may be related to the direct impact on
atherosclerosis, increased blood pressure as well as link to diabetes. However, the
direct causes of increased inflammation are multiplicative. Among the inflammatory
markers frequently used in predicting CVD, IL-6, CPR and hsCRP were reported to be
most predictive of CVD. Though evidence supports an association between sleep and
CVD risk, Sleep quality is not a consistent predictor of CVD. Furthermore, the etiology
of sleep difficulties is not always clear.
Despite evidence supporting the influence of depression, inflammation and sleep
on CVD, uncertainties remain. Therefore, supporting, this secondary analysis of the
data from The Heart Strategies Concentrating on Risk Evaluation study to evaluate the
predictive effect of depressive symptoms, inflammation, and sleep quality on the risk for
developing a major adverse cardiac event.
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CHAPTER THREE:
METHODS
Chapter III presents the study design, rationale, sample and setting, and measures
utilized from the Heart Strategies Concentrating on Risk Stratification study (Heart
SCORE). This chapter also provides the aims and rationale of this secondary analysis.
The analytic plan includes the specific variables that were considered, and methods
used for statistical analyses of the data.
Study Design
This study is a secondary analysis of the data obtained from the Heart Strategies
Concentrating on Risk Evaluation (Heart SCORE), a longitudinal prospective cohort
study conducted over a 14-year period. The ongoing Heart SCORE study has been
prospectively examining cardiovascular disease (CVD) risk factors and CVD events on
an initial cohort of 2,000 enrolled adults ages 45 to 75 at study entry. The data collection
was started in 2003 is still active with data obtained up to November 2017 for this
analysis (Bambs et al.,2011). The current study explores the predictive relationship
between the modifiable risk factors, depressive symptoms, inflammation, and quality of
sleep, on the risk of developing cardiovascular disease.
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Sample and Setting
As referenced above, the Heart SCORE study includes 2000 adults ranging from
the ages of 45 to 75 years, who were living within the greater Pittsburgh, Pennsylvania
area at the time of enrollment. The original aims of the study were to improve risk
stratification and identify racial disparities within a population (Bambs et al., 2011). To
meet the aims of the study, a priority was placed on oversampling of minorities to
include approximately equal representation of White and Black subjects to permit
stratified analyses by race in relation to risk of CVD. The specific target recruitment
goals included 2,000 participants, 50% Black, 1,000 participants with low CVD risk, as
measured by the Framingham risk score, 1,000 with intermediate or elevated risk, and
200 with established CVD. Recruitment strategies included mailings, referrals, and
advertisements. To meet approximate proportional representation from Black
communities, local organizations and church groups were targeted (Bambs et al., 2011).
Rationale for the Primary Study
The Heart SCORE study was designed with the aim of improving risk
stratification, including identification of mechanisms associated with racial disparities for
population differences in CVD (Bambs et al, 2011). To achieve this goal, after a
baseline evaluation, subjects underwent annual visits which included measurements of
traditional and emerging CVD risk factors, tabulation of adverse events and
assessments of subclinical atherosclerosis.
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Rationale for Secondary Analysis
This secondary data analysis sought to make use of this large longitudinal study
to investigate the extent to which depressive symptoms, inflammation, and sleep quality
are independently associated with risk of experiencing a major adverse cardiac event.
To meaningfully lower the incidence of CVD and decrease mortality and disability, it is
imperative to identify potentially modifiable risk factors. Depressive symptoms,
inflammation, and sleep quality have been mentioned in numerous studies as having
potential predictive value for risk of development of CVD. These suggested
relationships provided the rationale for examination of the Heart SCORE data, a large
community-based cohort study with long-term follow-up.
Protection of Human Subjects
The University of Pittsburgh Institutional Review Board (IRB) approved the Heart
SCORE study to ensure that the privacy and rights of the participants were protected.
Participants in the Heart SCORE study were informed of any risks including the time
commitment for the longitudinal data collection. Written informed consent was obtained
from all participants. All data obtained was de-identified before transfer for analysis.
Approval from the Institutional Review Board at the University of South Florida was
obtained (Appendix A).
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Exclusion Criteria of the Heart SCORE Study
The Heart SCORE study excluded persons with major comorbidities, those in
poor health, or those with life expectancies less than five years. Additionally,
participants had to agree to participate in annual follow up exams. Those with previous
major cardiac events could be enrolled into the study.
Exclusion Criteria for Secondary Analysis
This secondary analysis excluded study subjects with a history of major adverse
cardiac event (MACE) prior to the baseline data collection. This included myocardial
infarction, cerebrovascular accident, or coronary revascularization. Additionally, persons
with missing outcome data were excluded. The original study collected data on 2,000
persons, of which, 105 were eliminated under the exclusion criteria for this secondary
analysis, resulting in a final N=1895.
Outcome Variables of the Current Secondary Analysis
The present analysis defined CVD and cardiovascular events as Major Adverse
Cardiovascular Events (MACE) using two closely related definitions.
Major Adverse Cardiac Event (MACE1) was defined as a diagnosis of at least one
of the following; cerebral vascular accident, acute ischemic syndrome, myocardial
infarction, coronary revascularization procedure, or experiencing cardiac death during
the duration of the study.

51

Major Adverse Cardiac Event (MACE6) was defined as diagnosis of one of the
following; cerebral vascular accident, acute ischemic syndrome, myocardial infarction,
or death from any cause during the duration of the study.
Predictor Variables of the Current Secondary Analysis
Depressive Symptoms/ CES-D Scale
The Heart SCORE study recognized the contribution of psychosocial health to
the physiological development of CVD. In this regard, the Center for Epidemiologic
Studies-Depression Scale (CES-D) was used as a measure of depressive symptoms.
The CES-D is a highly reliable tool with good reported internal consistency (alpha
coefficient of >0.85) designed to identify depressive symptoms rather than to diagnose
depression (Fischer, 2009; Smarr & Keefer, 2011). The items are scored on a scale of
0-3, with 0 indicating no symptoms and a 3 representing a greater severity of
symptoms. Traditionally, a score of 16 or higher is consistent with a diagnosis of
depression (Radloff, 1977). The total CES-D score can range from 0-60. Within Heart
SCORE, total scores ranged from 0-51, with a mean of 7, and 10 was at the 75th
percentile. Only 12% of the respondents had a value of 16 or greater at baseline. For
the present analysis, the data was divided into tertiles consisting of 3 groups of equal
participants, based on ranked values of the CES-D score and were coded as follows:
Group 0 (CES-D, 0-4); Group 1 (CES-D > 4-9); Group 2 (CES-D > 9).
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Inflammation/IL-6
The inflammatory response has been associated with multiple aspects of CVD,
most importantly atherosclerosis. The Heart SCORE study included several measures
of inflammatory biomarkers. Biomarkers that are frequently studied and associated with
CVD include both C-reactive protein (CRP) and interleukin-6 (IL-6). These markers are
associated with an acute phase stress reaction and systemic inflammation and have
shown consistent independent relationships with CVD (Langenberg, Bergstrom,
Scheidt-Nave, Pfeilschifter, & Barrett-Conner, 2006; Pearson et al., 2003).
In Heart SCORE, both, CRP and IL-6 were measured fasting with a venous
blood draw using standard laboratory technique at the University of Pittsburg Medical
Center clinical laboratory, at baseline. IL-6, with CRP measured as milligrams per
deciliter (mg/dL) and IL-6 measured as picograms per milliliter (pg/ml) (Bambs et al.,
2011). Due to high correlation of these measures, IL-6 was selected as the primary
measure of inflammation. Results of IL-6 were highly skewed to the right, ranging from
(0.038 to 48.27 pg/ml). Therefore, a natural log transformation was also considered.
The median IL-6 value was 1.708 with 95% of participants having a value less than 5.7
pg/ml. A plot of frequency of MACE6 by half unit of IL-6 seemed to show a continual
increase of events from 0 until about 2 pg/ml (the 60th -70th percentiles), and then a
leveling off until passing the 95th percentile.
Hence, for ease of interpretation, the data was divided into tertiles, containing
equal number of participants based on ranked values of IL-6. Tertile cut-points were
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(1.245 pg/ml and 2.28 pg/ml). Initial models indicated the risk of MACE (either 1 or 6)
was similar for the second and third tertiles of IL-6. Therefore, the later tertiles were
combined. Thus, IL-6 was treated as a dichotomous variable with the cut point at the
33.3rd percentile (1.245 pg/ml).
Sleep Quality / Insomnia Scale
Sleep quality was measured by The Insomnia Symptom Questionnaire (ISQ).
This included assessment of symptoms of insomnia experienced over the last month as
an overall measure of sleep quality. This 13-question self-report survey is widely used
to assess for sleep disorders and reportedly has a high Cronbach-α coefficient of 0.89
indicating good internal consistency (Okun et el., 2009). The proposed algorithm for
scoring the scale and identifying someone as having insomnia is as follows. (1) The
participant indicates trouble falling asleep, trouble waking during the night or sleep that
is unrefreshing (items 1, 2 or 5) frequently or always; (2) The participant has the
problem(s) indicated in (1) for 4 weeks or longer and (3) the participant indicates that
s/he has one or more daytime sequelae (items 6-13), “quite a bit,” or “always” (Okun et
al., 2009).
Within Heart SCORE, this tool was administered as a self-report and many
participants who indicated symptoms of insomnia did not answer the questions about
duration. Consequently, three new categories for sleep quality were defined: (1)
Participants who did not indicate difficulty falling asleep, difficulty staying asleep, or
sleep that is unrefreshing as frequently or always: (items 1, 2 or 5); (2) Participants who
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did indicate trouble falling asleep, trouble waking during the night, or sleep that is
unrefreshing as frequently or always, (items 1, 2 or 5) but did not select “quite a bit” or
“always” for any daytime sequelae; and (3) Participants who indicated trouble falling
asleep, trouble waking during the night or sleep that is unrefreshing as frequently or
always, and reported having one or more daytime sequelae (items 6-13), as “quite a
bit,” or “always”.
Covariates
Demographics
Age, gender, and race were included as covariates in every model. Race
included White, Black, and Other. Less than 4% of respondents self-classified
themselves as other. Statistical analysis of this population proved difficult and is often
marked non-determinant in tables or excluded from statistical analysis.
Smoking
Subjects were asked about smoking history. Self-reported use of cigarettes was
categorized as; current, former, and never a smoker. Smoking history was included in
all models as a categorical variable with two indicator variables representing current or
former smoker. The number of cigarettes smoked per day, number of years smoked,
and the number of years since quitting smoking were not available for analysis.
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Diabetes Mellitus
During the baseline screening process, subjects were asked to complete selfreport questionnaires. The questionnaire included a self-report of having diabetes, yes
or no? Are you being treated for diabetes, yes or no? Diabetes was entered all models
as a dichotomous variable.
Glucose
Baseline fasting venous glucose level, with standard analytical techniques were
entered as a continuous variable (Bambs et al., 2011).
Use of Antihypertensive Medications
Subjects were asked if diagnosed with hypertension, yes or no, and are you
currently taking medications for hypertension yes or no? Use of antihypertensive
medications was entered as a dichotomous variable.
Systolic Blood Pressure (SBP)
Systolic blood pressure was included as a continuous variable for analysis. Blood
pressures were obtained following the AHA gold standard within the Heart SCORE
study. Subjects were seated, with legs uncrossed for a minimum of 5 minutes prior to
taking the blood pressure. Experienced nurses using a manual sphygmomanometer
took the blood pressures. The blood pressures were taken with the appropriated sized
cuff and recorded twice, with a resting five minutes between readings. The average of
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the two readings was recorded as the sample blood pressure. Equipment was subject to
routine calibration and was replaced when reliable performance was not assured
(ACC/AHA, 2017, Bambs et al., 2011).
Obesity
The Heart (SCORE) study included measures for BMI, skin fold tests, waist
circumference and waist to hip ratio. The present analysis included continuous
measures of BMI (kg/m2) and waist circumference in centimeters as covariates.
Cholesterol
High-density lipoprotein (HDL). was included in the initial models.
Triglycerides (TRIG). was included in initial models.
Statin Medications as determined from the question: Are you
presently taking a “statin” medication? Yes or No, by a self-report questionnaire,
The laboratory lipid panel was obtained while participants were fasting for no less
than six hours and after resting for a period no less than fifteen minutes prior to blood
draw. The initial baseline lab studies of high-density lipoprotein (HDL), triglycerides
(TRIG), and low-density lipoprotein (LDL) were measured using standard laboratory
procedures. Follow up testing was completed using the Vertical Auto Profile test (VAP)
method. These 3 lipid measures were included in initial models and entered as
continuous measures. In addition, patients were asked if they were presently taking a
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lipid lowering medication classified as a “statin’ medication? This was included as a
dichotomous measure as a covariate
Statistical Analysis
The statistical analysis was guided by the aims of the study;
Aim 1
To prospectively evaluate the independent relationships between traditional
cardiac risk factors, depressive symptoms, inflammation, and sleep quality, on longterm risk of MACE1 and MACE6.

Initially, univariate analysis of traditional risk factors for CVD were examined for
association with MACE1 and MACE6 by use of Cox proportional hazards regression.
This approach led to the selection of a final set of traditional risk factors to be included
in all models. The variables that were screened included BMI, waist circumference,
diabetes mellitus, systolic BP and use of hypertensive medications, HDL, TRIG, use of
lipid-lowering agents, and glucose. Through stepwise selection, a variable was retained
for future models based on the Wald Chi-Squared test, and the association with either
MACE1 or MACE6 with selection p-values set at 0.2. The Wald Chi-Squared Test is
used to test the null hypothesis that the effect from the predictor variable is 0. A
significant p-value from a Wald Chi-Squared Test rejects the null, indicating a significant
effect of the variable on the outcome of interest (Tabachnick, & Fidell, 2007). Retained
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variables are subsequently indicated in Table 2, ad race was included in all models
irrespective of statistical significance due to presumed biological relevance.

Once the set of traditional risk factors was identified, separate Cox Proportional
hazard models were fit adding in (separate models) the three novel risk factors of
interest: depressive symptoms, IL-6, and insomnia. The use of Cox proportional
hazards regression was chosen because it can accommodate both continuous and
categorical predictor variables and is able to provide individual effects known as hazard
ratios (HR) for multiple predictors simultaneously. However, with the use of this method,
there are a few assumptions that must be considered (Tabachnick, & Fidell, 2007).
1.) Independence between individual subjects.
2.) Multiplicative relationship between hazard and predictors.
3.) The hazard ratio is constant (i.e. proportional) over the time tested.
4.) The hazard ratio represents a 1 unit of change in risk of the outcome of
interest holding all other predictors constant.
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Aim 2
To prospectively evaluate whether gender modifies the relationships between
depressive symptoms, inflammation, and sleep quality on long-term risk of MACE.
To determine whether the effects of IL-6, depressive symptoms and insomnia in
predicting MACE1 or MACE6 differed between males and females, three additional
models were run: Interaction Models 1-3 included the interaction term(s) between
gender with depressive symptoms, gender with IL-6 and gender by insomnia,
respectively. P-values from the interaction terms were examined to evaluate potential
effect modification. In addition, in stratified analyses, respective hazard ratios for
depressive symptoms, IL-6, and insomnia were summarized for males and females,
respectively.
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CHAPTER FOUR:
DATA ANALYSIS
This chapter provides a descriptive summary of the data obtained from the Heart
Score Study and presents the data analysis based on the specific aims of this study.
The most recent follow-up data, including information on major cardiac events,
was collected as of November of 2017 and covers a mean of 9.9 years. Table 1.
provides summary statistics on the participants and variables of interest in this study.
Continuous variables are tested with student t-tests and presented as mean and
standard deviation, while categorical variables are presented as frequencies and
percentages and were analyzed with Chi-Square tests.
Descriptive Statistics
The participants upon entrance into the study included 1,256 females (66%), 639
males (34%), ranging from 45 to 75 years of age with a median age of 60 years. Race,
provided by participants as a self-report, was nearly equally represented with Blacks
42% (n=799), Whites 55% (n=1047), and Other 3% (n=49). Participants were followed
for the development of a major adverse cardiac event (MACE). Six percent, (n =113) of
the 1,895 participants experienced a cardiac event as defined by the MACE1 criteria.
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Table 1. Descriptive Statistics of the Sample

%Female
Race
White
Black
Other
BMI kg/m2

55 (48.67)

MACE1
No
(n=1782)
58.63 ± 7.41
1201
(67.40)

64 (56.64)
47 (41.59)
2 (1.77)
30.56±6.33

983 (55.16)
752 (42.20)
47 (2.64)
30.01±6.36

Waist (CM)
Smoking
Current smoker
Former smoker
Never smoker
Diabetes Mellitus
Systolic Blood
Pressure (mmHg)
BP meds
HDL

99.78±15.56

95.59±15.12

15 (13.27)
52 (46.02)
46 (40.71)
24 (21.43)

177 (10.02)
730 (41.31)
860 (48.67)
157 (8.86)

144.2±20.72
59 (52.21)
53.44±13.00
126.5
±58.57
30 (26.55)
105.4±32.23
17 (17.17)
82 (82.83)
7.00± 7.62

568 (34.30)
1088
(65.70)
6.84±7.98

38 (33.63)
35 (30.97)
40 (35.40)

641 (36.42)
544 (30.91)
575 (32.67)

64 (64.54)
22 (21.15)
18 (17.13)

991 (60.57)
356 (21.76)
289 (17.67)

Age Mean/SD

Triglycerides
Statin meds
Glucose
IL-6
Lowest tertile
Upper two tertiles
DEP S /CES-D
Dep S
Low CES-D
Mid CES-D
High CES_D
Sleep Quality
Insomnia
None/low freq.
Hi freq./low day
Hi freq./hi day

Yes (n=113)
62.81±7.42

p-value
<0.001

Yes (n=160)
63.23±- 7.46

<0.001
0.835

76 (47.50)

pvalue
<0.001
<0.001
0.180

99.16±16.23

962 (55.45)
725 (41.79)
48 (2.77)
30.02±6.35
95.54
±15.04

<0.001

29 (18.24)
67 (42.14)
63 (39.62)
29 (18.24)

163 (9.47)
715 (41.55)
843 (48.98)
152 (8.81)

<0.001

135.7±19.35
700 (39.39)
57.99±15.00

<0.001
0.007
0.002

142.8±20.08
79 (49.38)
55.18 ±14.86

135.6±19.37
680 (39.31)
57.94±14.91

<0.001
0.013
0.027

122.9±76.70
336 (18.91)
98.27±25.32

0.623
0.046
0.004
<0.001

126.2± 80.34
36 (22.50)
104.0 ±24.06

122.8±75.31
330 (19.08)
98.22±25.94

0.596
0.294
0.007
<0.001

27 (19.15)
114 (80.85)
7.04±7.23

558 (34.57)
1056
(65.43)
6.84±8.03

48 (30.38)
54 (34.18)
56 (35.44)

631 (36.79)
525 (30.61)
559 (32.59)

93 (63.70)
28 (19.18)
25 (17.12)

962 (60.35)
350 (21.96)
282 (17.69)

0.380
0.005
0.216

0.838
0.791

85 (53.13)
74 (46.25)
1 (0.63)
30.26± 6.51

MACE6
No
(n=1735)
58.47± 7.35
1180
(68.01)

0.981

0.656
0.005
0.001

0.744
0.274

0.688

Ŧ insomnia complaints include Trouble falling asleep, trouble with waking during the night and unrefreshing sleep. For those with
complaints, day time problems are assessed. Note. ***, **, * denotes significant, p=<0.001, p<=0.01, p<=0.05, respectively. B
denotes significance is borderline or close to significant, 0.05 =<p<0.1 Depressive symptoms (DEP S)
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The rate of MACE1 was 9% for males, 4% for females, and by race, 6% for whites, 6%
for blacks, and 4% for other. Nine percent, (n=160) of the 1,895 participants developed
CVD as defined by MACE6. The rate of MACE was 13% for males, 6% for females, and
by race, 8% for whites, 9% for blacks, and 2% for other.
Analysis for AIM 1
Independent relationships between traditional predictor variables and the
outcome variables of MACE are seen in Table 2, as determined by stepwise selection
(Model 1 for MACE 1 and Model 2 for MACE 6). Thus, each model thereafter was
adjusted for established cardiovascular risk factors consisting of gender, race, diabetes,
smoking, systolic blood pressure, and HDL cholesterol. Cox proportional hazard
models were fit with the purpose of evaluating relationships between the aboveTable 2. Stepwise Selection Traditional Risk factors

Parameter
N=
Age (years)
Gender
Race
Diabetes
Smoking
Waist in (cm)
BMI (kg/m2)
HDL mg/dL
Triglycerides (mg/dL)
Use of Statin med
Systolic BP (mm Hg)
Antihypertensive meds
Glucose mg/dL

MACE1
p-value
113
<.0001
0.028
0.737
0.004
0.148
0.292
0.354
0.077
0.289
0.673
0.022
0.750
0.876

Selected
1782
XXX
XXX
XXX
XXX
XXX

XXX

XXX

MACE6
p-value
160
<.0001
0.0002
0.1286
0.0018
<0.0001
0.4247
0.8124
0.6336
0.4221
0.918
0.072
0.669
0.790
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mentioned traditional risk factors, and then the novel risk factors of interest which
included depressive symptoms, inflammation, and sleep quality. This approach was
used for estimating long-term risk of either MACE1 or MACE6. These models are
provided to illustrate the p-value criteria used for inclusion of covariates, realizing that
race was included uniformly due to presumed biological importance. The models
provided the basis for subsequent entry of the novel predictors of interest to estimate
the independent relationship with risk of MACE.
Effect of Traditional Risk Factors for CVD
Table 3 shows the hazard ratios with 95% confidence intervals, for the traditional
risk factors on developing MACE. As age increases by one year, the estimated adjusted
higher risk for developing CVD was approximately 7% for MACE1 and 9% for MACE6.
Males were at significantly higher risk of MACE with adjusted hazard ratios of 1.80 and
2.20 for MACE1 and MACE 6, respectively (i.e. approximately 2-fold higher risk overall).
Independent Effect of Diabetes and Traditional Risk for CVD

Having diabetes more than doubled the risk for the development of MACE for
both MACE1, HR 2.34, 95% CI [1.46, 3.77], and MACE6 HR 2.10, 95% CI [1.37, 3.20]
categories (see Table 3). Race was not associated with risk of development of CVD
within this population group.
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Table 3. Effect of Traditional Risk Factors on Risk for CVD
MACE1

Parameter
Age (years)
Gender
Female
Male
Race
White
Black
Other
Diabetes
Smoking
Non- Smoked
Current Smoker
Former Smoker
High-Density
Lipoprotein (mg/dL)
Syst Blood Pressure
(mm Hg)

Hazard
Ratio
1.072

95% HR
Confidence
Interval
[1.043, 1.102]

MACE6

Sig
<.0001
0.003

Hazard
Ratio
1.089

95% HR
Confidence
Interval
[1.064, 1.115]

1.804

(Reference)
[1.214, 2.681]

2.196

(Reference)
[1.565, 3.082]

0.902
0.568
2.344

(Reference)
[0.601, 1.353]
[0.139, 2.328]
[1.459, 3.767]

1.224
0.181
2.096

(Reference)
[0.873, 1.717]
[0.025, 1.309]
[1.372, 3.201]

1.813
1.084

(Reference)
[0.993, 3.309]
[0.722, 1.626]

0.05

2.641
0.937

(Reference)
[1.645, 4.242]
[0.658, 1.334]

0.987

[0.972, 1.001]

0.07

1.013

[1.004, 1.023]

0.007

.0004

0.998
1.009

Sig
<.0001
<.0001

.0006

<.0001

[0.985, 1.009]
[1.001, 1.017]

0.03

Independent Effect of Smoking and Traditional Risk Factors for CVD
The effect of being a smoker was highly significant (p<0.0001). Those who
smoke were 1.8 times more likely to develop MACE1 than non-smokers and 2.6 times
greater risk for developing CVD as defined by MACE6 see (Table 3). Persons reporting
having been former smokers had risks near that of a nonsmoker with no significant
increase in risk.
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Independent Effect of High-Density Lipoprotein (HDL) and Traditional
Risk for CVD
HDL cholesterol was not associated with future risk of MACE1 or MACE yet was
in the direction of higher values being associated with overall lower risk -- see Table 3.
Independent Effect of Systolic Blood Pressure and Traditional Risk Factors on
Risk for CVD.
Higher systolic blood pressure was statistically associated with a higher risk of
both MACE1 and MACE6 classifications of CVD. The hazard ratio represents a 1 unit of
change (Tabachnick, & Fidell, 2007). By extension, a 10-mm Hg increase in systolic
blood pressure increased the risk of MACE1 by approximately 13%.
Independent Effect of Depressive Symptoms and Traditional Risk Factors on Risk
of CVD
When adding the novel predictor of depressive symptoms (see Table 4) into the
model with the traditional risk factors, there was evidence of mild to moderate increase
in the risk of CVD. Specifically, the middle and higher tertiles of depressive symptoms
suggested an increase in the risk of MACE1 by 21% and 43%, respectively. These did
not achieve statistical significance. However, the middle and higher tertiles of
depressive symptoms was statistically associated with a higher risk of MACE6 with
adjusted hazard ratio estimates of 1.65 and 1.68, respectively.
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Table 4. Traditional Risk Factors Adding Depressive Symptoms (CES-D) on
MACE
MACE1

Parameter
Age (years)
Gender

Hazard
Ratio
1.075

Female
Male

95% HR
Confidence
Interval
[1.046, 1.105]

MACE6

Sig
<0.0001

Hazard
Ratio
1.095

(Reference)
1.89

[1.264, 2.817]

95% HR
Confidence
Interval
[1.069, 1.122]

Sig
<.0001

(Reference)
0.0019

2.35

[1.665, 3.323]

<.0001

Race
(Reference)

White
Black
Other
Diabetes
Smoking

0.91
0.57
2.33

Non- Smoker
Current Smoker
Former Smoker
High-Density Lipoprotein
(mg/dL)
Systolic Blood Pressure
(mm Hg)

(Reference)

[0.607, 1.366]

1.219

[0.866, 1.715]

[0.140, 2.343]

0.19

[0.026, 1.367]

2.162

[1.415, 3.303]

[1.452, 3.749]

0.0005

(Reference)

0.0004

(Reference)

1.72

[0.938, 3.148]

0.079

1.08

[0.722, 1.624]

0.99

[0.973, 1.00]

0.082

1.01

[1.003, 1.022]

0.010

2.554

[1.582, 4.125]

0.935

[0.654, 1.335]

0.997
1.009

[0.985, 1.009]
[1.000, 1.017]

0.042

DEP S / (CES-D)
CES-D, Low (0-4)

(Reference)

(Reference)

CES-D, Mid (>4-9)

1.21

[0.757, 1.919]

0.430

1.648

[1.107, 2.454]

0.013

CES-D, Higher (>9)

1.43

[0.906, 2.259]

0.124

1.678

[1.116, 2.522]

0.012

Note. ***, **, * denotes significant, p=<0.001, p<=0.01, p<=0.05, respectively. B denotes significance is borderline or close to
significant, 0.05 =<p<0.1 Depressive symptoms (DEP S)
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Independent Effect of Inflammation and Traditional Risk Factors on Risk for CVD
When adding the novel predictor of IL-6, hazard ratio estimates for the traditional
risk factors were only nominally attenuated. Specifically, age, gender, diabetes,
smoking, and systolic BP all remained significant risk factors. Importantly, the effect of
an elevated IL-6 on risk of developing CVD was substantial for both MACE1, HR 2.45,
95% CI [1.41, 4.25]; p= 0.001 and MACE6 HR 2.1, 95% CI [1.36, 2.28]; p=<0.001 (see
Table 5). These results indicated that high inflammation is a strong, independent risk
factor for long-term risk of MACE.
Table 5. Traditional Risk Factors adding Inflammation (IL-6) on MACE
MACE1

Parameter
Age (years)
Gender
Female
Male
White
Black
Other
Diabetes
Never Smoked
Current Smoker
Former Smoker
High-Density
Lipoprotein (mg/dL)
Systolic Blood
Pressure (mm Hg)
Inflammation IL-6
IL-6 (pg/ml) (low)
IL-6 (pg/ml) (Higher)

Hazard
Ratio
1.077

1.85
0.815
0.576
1.931
1.968
0.921

95% HR
Confidence
Interval
[1.046, 1.109]

(Reference)
[1.206, 2.844]
(Reference)
[0.523, 1.270]
[0.140, 2.370]
[1.139, 3.274]
(Reference)
[1.067, 3.630]
[0.593, 1.429]

0.99

[0.975, 1.006]

1.012

[1.001, 1.022]

(Reference)
2.445
[1.407, 4.248]

MACE6

Sig
<.0001
0.004

Hazard
Ratio
1.090

2.39

0.014
0.030
0.2220
.

1.137
0.181
1.569
2.629
0.834
0.999
1.009

0.001

95% HR
Confidence
Interval
[1.063, 1.117]

(Reference)
[1.666, 3.454]
(Reference)
[0.790, 1.633]
[0.025, 1.309]
[0.973, 2.531]
(Reference)
[1.615, 4.282]
[0.571, 1.218]

Sig
<.0001
<.0001

0.064
0.0001

[0.986, 1.012]
[1.001, 1.018]

(Reference)
2.111
[1.357, 3.285]

0.039

0.0009
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Independent Effect of Sleep Quality / Insomnia on Risk for CVD
The inclusion of mild or more severe insomnia was not statistically associated
with risk of either MACE1 or MACE6 beyond the influence of traditional risk factors (see
Table 6).

Table 6. Traditional Risk Factors adding Sleep Quality (Insomnia) on MACE
MACE1
Hazard
Ratio
1.077

95% HR
Confidence
Interval
[1.046, 1.109]

Parameter
Age (years)
Gender
Female
(Reference)
Male
1.998
[1.31, 3.021]
Diabetes
2.303
[1.396, 3.800]
Smoking
Non- Smoker
(Reference)
Current Smoker
2.136
[1.154, 3.953]
Former Smoker
1.076
[0.702, 1.649]
High-Density
Lipoprotein(mg/dL)
0.987
[0.972, 1.002]
Syst Blood Pressure (mm Hg) 1.010
[1.00, 1.021]
Sleep Quality- Measured by Insomnia Scale (IS)
IS (No symptoms)-1
(Reference)
IS (Mild) -2
1.031
[0.633, 1.677]
IS (Daytime bother)-3
1.197
[0.704, 2.038]

MACE6

Sig
<.0001
0.001

0.001

0.015

0.08
0.043

Hazard
Ratio
1.093

95% HR
Confidence
Interval
[1.066, 1.121]

2.404
2.202

(Reference)
[1.686, 3.429]
[1.288, 3.173]

3.063
0.971

(Reference)
[1.838, 5.023]
[0.668, 1.410]

0.996
1.008

[0.984, 1.009]
[0.999, 1.016]

0.914
1.189

(Reference)
[0597, 1.400]
[0.751, 1.881]

Sig
<.0001
<.0001

0.002

<.0001

0.091

Note. Ŧ Sleep Quality/insomnia complaints 1. include Trouble falling asleep, trouble with waking during the night and
unrefreshing sleep. For those with complaints, day time problems are assessed. Blood Pressure (BP)

Collective Effect of Traditional and Novel Risk Factors
When both traditional and all three novel risk factors were considered, adjusted
hazard ratios tended to be attenuated to a small extent (see Table 7). Nonetheless, with
this full set of risk factors, older age, male gender, diabetes, current smoker, and high
inflammation remained strong independent risk factors for both MACE1 and MACE6.
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Depressive symptoms in the upper tertile indicated a higher adjusted risk for MACE6
but not for MACE1. The estimated independent effect of high IL-6 was substantial with
adjusted hazard ratios of 2.77 and 2.34 for MACE1 and MACE6, respectively
Table 7. Effect of Traditional Risk Factors adding, Depressive Symptoms,
Inflammation and Sleep Quality
MACE1

Parameter
Age (years)
Female
Male
White
Black
Other
Diabetes
Never- Smoked
Current Smoker
Former Smoker
HDL (mg/dL)
Systolic BP (mm Hg)
CES-D, Low (0-4)
CES-D, Mid (>4-9)
CES-D, Higher (>9)

Haza
rd
Ratio
1.087

95% HR
Confidence
Interval
[1.054, 1.122]
(Reference)
2.141 [1.36, 3.364]
(Reference)
[0.513, 1.298]
[0.046, 2.45]
1.915 [1.101, 3.330]
(Reference)
2.147 [1.138, 4.048]

MACE6

Sig
<.0001
0.001

0.812
0.337

0.021
0.018

0.891
0.991
1.008

[0.562, 1.411]
[0.975, 1.008]
[0.997, 1.019]
(Reference)
1.109 [0.659, 1.864]
1.276 [0.730, 2.218]

I-6 (pg/ml) (low)
(Reference)
IL-6 (pg/ml) (Higher)
2.767 [1.536, 4.98]
0.0007
Sleep Quality- Measured by Insomnia Scale (IS)
IS (No symptoms)-1
(Reference)
IS (Mild) -2
1.031
[0.633, 1.677]
IS (Daytime bother)-3
1.197
[0.704, 2.038]

Hazar
d
Ratio
1.100

95% HR
Confidence
Interval
[1.070, 1.131]
(Reference)
2.799
[1.897, 4.131]
(Reference)
1.111
[0.754, 1.637]
(Non-determinant)
1.558
[0.963, 2.59]
(Reference)
2.849
[1.699, 4.777]

Sig
<.0001
0.001

0.08
<0.0001

0.855
01.00

[0.572, 1.278]
[0.986, 1.014]
1.007
[0.998, 1.017]
(Reference)
1.465
[0.941, 2.280]
1.63
[1.009, 2.651]

0.090
0.046

2.339

(Reference)
[1.119, 3.775]

0.005

0.914

(Reference)
[0597, 1.400]

1.189

[0.751, 1.881]

Note. High-Density Lipoprotein (HDL), Interleukin-6 (IL-6), Depressive symptoms (DEP S) / measured by CES-D
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Data Analysis Aim 2 -The Effect of Gender
Analysis was conducted to prospectively evaluate whether gender modifies the
relationships between sleep quality, depressive symptoms, and inflammation and longterm risk of MACE. Summary statistics on the participants and variables separated by
gender is presented in Table 8a for females and Table 8b for males. Student t-tests are
reported for continuous variables, presented as mean and standard deviation.
Categorical variables were analyzed with Chi-Square tests and presented as
frequencies and percentages. In comparing the overall gender specific summary
statistics, no significant differences were identified. To examine the effects of gender on
the relationships between depressive symptoms inflammation and insomnia symptoms,
models were run to test for interaction with gender.
Effect of Gender and Depressive Symptoms on Risk for CVD
Table 9 provides results from three tests for the effect of gender. The first model
shown demonstrates a joint model where the variables gender and depressive
symptoms are combined (multiplied) in relation to predicting MACE (i.e. Females with
high depressive symptoms). Wald chi-square test for these tests were not significant.
However, this approach to investigating effect modification is often underpowered and
inconclusive, in part, because joining these variables results in less precision and a
large (e.g. four-fold) increase in the variance for the interaction term.
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Table 8a.
Descriptive Statistics of Participants by Gender (Females)
MACE1
FEMALES

Yes

No

Parameter

n=55

n=1201

Age M/SD

62.65 ± 7.81

58.55 ± 7.40

%Female

55 (48.67)

1201 (67.40)

Race

MACE6
p-value

Yes

No

n=76

n=1180

<0.001

63.79 ± 7.64

58.40 ± 7.33

<0.001

<0.001

76 (47.50)

1180 (68.01)

<0.001

0.976

p-value

0.674

White

30 (54.55)

642 (53.46)

38 (50.0)

634 (53.73)

Black

24 (43.6)

533 (44.38)

37 (48.68)

520 (44.07)

BMI kg/m2 M/SD

30.15 ± 6.32

30.19 ± 6.71

0.966

29.71 ± 589

30.22± 6.74

0.519

Waist in cm

94.68 ±15.88

93.69±15.43

0.648

95.51±15.88

93.68±15.42

0.658

Other

Smoking

0.868

Current smoker

6 (10.91)

108 (9.07)

Former smoker

21 (38.18)

Never smoker

28 (50.91)

Diabetes
Systolic Blood Pressure
(mmHg)

0.01

0.377
10 (13.16)

104 (8.89)

485 (40.72)

27 (35.53)

479 (40.94)

598 (50.21)

39 (51.32)

587 (50.17)

109 (9.13)

0.008

15 (19.74)

105 (8.98)

<0.002

142.8 ±19.18

135.3±20.09

0.007

142.0±19.23

135.2±20.10

0.004

Hypertensive meds

30 (54.55)

487 (40.58)

0.040

39 (51.32)

478(40.54)

0.064

HDL

57.98 ±12.45

61.51±14.99

0.086

60.70±13.56

61.39±14.98

0.699

Triglycerides

134.3 ±63.57

120.2±75.39

0.172

123.3±63.46

120.7±75.63

0.771

Statin medication

13 (23.64)

217 (18.08)

0..298

18 (23.68)

212 (17.98)

0.213

Glucose

106.4±40.27

96.94±24.93

0.008

104.5±25.73

96.91. ±25.7

0.014

Lowest tertile

9 (18.00)

336 (30.08)

12 (17.91)

333 (30.27)

Upper two tertiles

41 (82.00)

781 (69.92)

55 (82.09)

767 (69.73)

IL-6

0.067

Depressive symptoms

0.031

0.138

0.214

CES-D, Low (0-4)

13 (23.64)

391 (32.97)

18 (24.00)

386 (33.10)

CES-D, Mid (>4-9)

16 (29.09)

384 (32.38)

25 (33.33)

375 (32.16)

CES-D, Higher (>9)

26 (17.27)

411 (34.65)

32 (42.67)

405 (34.73)

Sleep Quality- Measured by Insomnia Scale (IS)

0.502

0.999

IS (No symptoms)-1

24 (50.00

639 (58.14)

38 (57.58)

625 (57.82)

IS (Mild) -2

12 (25.00)

246 (22.38)

15 (22.73)

243 (22.48)

IS (Daytime bother)-3

12 (2500)

214 (19.47)

13 (19.70)

213 (19.70)

Note. 'Insomnia Category 1. Low frequency of or no complaints, 'Insomnia Category 2. High frequency of complaints, low bother Insomnia
Category 3. High Frequency of complaints, high bother. Blood Pressure (BP)
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Table 8b. Descriptive Statistics of Participants by Gender (Males)
MALES
Parameter
Age Mean/SD

MACE1

MACE6

Yes
n=58

No
n=581

p-value

Yes
n=84

No
n=555

p-value

62.97 ± 7.09

58.79 ± 7.46

<0.001

62.71 ± 7.30

58.63 ± 7.41

<0.001

Race

0.976

0.674

White

34 (58.62)

341(58.69)

47 (55.95)

328 (59.10)

Black

23 (39.66)

219 (37.69)

37 (44.05)

205 (36.94)

Other

1

21

0

22

BMI kg/m2 M/SD

30.94 ± 6.38

29.63 ± 5.56

0.095

30.76 ±7.03

29.60± 5.40

0.081

Waist in cm

104.5 ±13.76

99.57 ±13.62

0.009

103.3 ± 15.48

99.54 ± 13.35

0.021

Smoking

0.107

Current smoker

9 (15.52)

Former smoker
Never smoker
Diabetes Mellitus
Systolic BP (mmHg)
Takes BP meds

0.001

69 (11.98)

19 (22.89)

59 (10.71)

31 (53.45)

245 (42.53

40 (48.19)

236 (42.83)

18 (31.03)

262 (45.49)

24 (28.92)

265 (46.46)

13 (22.81)

48 (8.30)

<0.001

14 (16.87)

47 (8.51)

0.016

145.5 ±22.17

136.8 ±17.68

0.001

143.4 ±20.91

136.7 ±17.71

0.002

29 (50.00)

213 (36.92)

0.051 B

40 (47.62)

202 (36.66)

0.054

HDL

49.14 ±12.10

50.70 ± 12.13

0.35

50.27 ± 14.29

50.60 ±11.78

0.816

Triglycerides

119.1 52.88

128.4±79.1

0.379

12.87±93.16

127.74.50

0.881

17 (29.31)

119(20.62)

0.125

18 (21.43)

118(21.42)

0.998

104.4 ± 22.43

101.0 ± 25.90

133.6 ± 21.52

101. ± 26.16

Lowest tertile

8 (16.33)

232 (43.04)

15 (20.27)

225 (43.77)

Upper two tertiles

41 (83.67)

307 (56.96)

59 (79.73)

289 (56.23)

Statin medication
Glucose
IL-6

0.333
<0.001

Depressive symptoms
CES-D, Low (0-4)

0.138
25 (43.10)

250 (43.55)

30 (36.14)

245 (44.63)

CES-D, Mid (>4-9)

19 (32.76)

160 (27.87)

29 (34.94)

150 (27.32)

CES-D, Higher (>9)

14 (24.14)

164 (28.57)

24 (28.92)

154 (28.05)

55 (68.75)

337 (65.69)

13 (16.25)

107 (20.86)

Sleep Quality- Measured by Insomnia Scale (IS)
IS (No symptoms)1
40 (71.43)
352 (65.55)
IS (Mild) -2
IS (Daytime bother)3

10 (17.86)
6 (10.71

110 (20.48)
75 (13.97)

0.387
<0.001

0.214

0.661

0.624

12 (15.00)

69 (13.45)

Note. 'Insomnia Category 1. Low frequency of or no complaints, 'Insomnia Category 2. High frequency of complaints, low bother Insomnia
Category 3. High Frequency of complaints, high bother. Blood Pressure (BP)
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The next test for effect modification by gender is a stratified model. In other words,
genders are separated for analysis. This model illustrates females with higher
depressive symptoms have nearly double the risk for MACE1 (HR=1.95) and MACE6
(HR=1.82).

Table 9. Gender by Depressive Symptoms Interaction on MACE
MACE1

Parameter
DEP S p-values
Gender X Mid (CES-D)
Gender x High (CES-D)
DEP S– Female
(CES-D) Low (0-4)
(CES-D) Mid (>4-9)
(CES-D) Higher (>9)
DEP S- Male
(CES-D) Low (0-4)

Haza
rd
Ratio

95% HR
Confidence
Interval

MACE6

Sig

Hazard
Ratio

95% HR
Confidence
Interval

0.686
0.185

1.376
1.957

(Reference)
[0.661, 2.865]
[0.999, 3.834]

0.69
0.06

0.905
0.704
(Reference)
1.703
[0.919, 3.157]
1.820
[1.000, 3.312]

(Reference)

(CES-D) Mid (>4-9)
(CES-D) Higher (>9)
Gender by DEP S
Female x Low (CES-D)
Male x Low (CES-D)
Female x Mid (CES-D)

1.131
1.035

Male x Mid (CES-D)
Female x High (CES-D)
Male x High (CES-D)

2.838
1.957
2.597

[0.616, 2.075]
[0.532, 2.014]

(Reference)
2.50
[1.265, 4.979]
1.376 [0.661, 2.856]
[1.370, 5.880]
[0.999, 3.834]
[1.192, 5.658]

Sig

NS
0.04 *

(Reference)
NS
NS

1.621
1.551

**
NS

(Reference)
2.533
[1.368, 4.687]
1.703
[0.919, 3.157]

**
B

4.105
1.820
3.935

***
*
***

**
*
*

[0.961, 2.734]
[0.885, 2.727]

[2.211, 7.622]
[1.000, 3.312]
[2.050, 7.553]

0.07
0.124

Note. ***, **, * denotes significant, p=<0.001, p<=0.01, p<=0.05, respectively. B denotes significance is borderline
or close to significant, 0.05 =<p<0.1 Depressive symptoms (DEP S)
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Therefore, females with depressive symptoms within the highest tertile of (CESD) scores are at an increased risk for developing CVD compared to females with low
levels of depressive symptoms. For men, depressive symptoms were not a significant
predictor of MACE, however the hazard ratios were >1 indicates a suggestion of
depression being associated with risk of MACE in males. The third analysis created
indicator variables for combinations of gender and tertiles of depression. Males at every
level (i.e. irrespective of level of depressive symptoms) had a higher risk of MACE as
compared to women. Overall, results indicated that depressive symptoms were
associated with higher risk of MACE in both genders, while not significantly different
between genders.

Table 10. Gender by IL-6 Interaction on MACE
MACE1

Parameter
Gender x IL-6
Interaction
Effect of IL-6 High x
Low
Among Females
Among Males

Hazard
Ratio

95% HR
Confidence
Interval

MACE6

Sig

Hazard
Ratio

95% HR
Confidence
Interval

0.208

1.717
3.441

[0.822, 3.586]
[1.529, 7.744]

NS
**

Gender x IL-6 Combination
(Reference)
Low IL-6 x Female
Low IL-6 x Male
1.036
[0.380, 2.822]
High IL-6 x Female
1.717
[0.822, 3.586]
High IL-6 x Male
3.564
[1.662, 7.639]
RERI Male IL-6
3.564-1.036-1.717+1 =
Interaction
1.811

NS
NS
**

Sig
0.368

1.688
2.506

[0.893, 3.193]
[1.383, 4.541]

NS
**

(Reference)

0.29

1.740
[0.793, 3.816]
1.688
[0.893, 3.193]
4.360
[2.258, 8.416]
4.360 -1.740-1.688+1
=1.932

NS
NS
***
0.026
*

Note. ***, **, * denotes significant, p=<0.001, p<=0.01, p<=0.05, respectively. B denotes significance is
borderline or close to significant, 0.05 =<p<0.1
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Effect of Gender on Inflammation /IL-6
As indicated in stratified analysis in Table 10, the effect of high IL-6 on long term
risk of CVD was substantial and was higher in males than in females. Specifically, for
MACE1, a high IL-6 in males resulted in an adjusted hazard ratio of 3.56 in males 95%
CI [1.66, 7.64] as compared to an adjusted hazard ratio of 1.72 in females, 95% CI
[0.82, 3.59]. Corresponding estimates for the MACE 6 definition were 4.36 in males
95% CI [2.26, 8.42] compared to 1.69 in females, 95% CI [0.89, 3.19]. Although these
apparent gender differences did not reach statistical significance in the formal test of
interaction, the evidence indicated that high IL-6 is a strong independent risk factor for
long-term risk of CVD, particularly in males.
The calculation of the relative excess risk due to interaction (RERI) computed by
the delta method is shown at the bottom of Table 10 (Li & Chambless,2007). The RERI
for being male and having high IL-6 was 1.81 for MACE1 and 1.93 for MACE6,
indicating a near double of risk among males.
Effect of Gender on Sleep Quality
Sleep quality measured by Insomnia questionnaire on all three categories of
sleep quality was not a significant risk factor for MACE for either gender (Table 11).
The differences in the ratios for males and females did not reach statistical significance
(all interaction p-values were greater than 0.15). Moreover, for males, hazard ratio
estimates for long-term risk of CVD in relation to insomnia were below the null value of
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1.0, thereby indicating no increased risk. For females, hazard ratios associated with
insomnia were only nominally above the null value of 1.0, again, indicating essentially
no exceed risk of CVD.

Table 11. Gender by Sleep Quality Interaction on MACE
MACE1

Parameter
Interaction p-values
Gender x Insomnia 2
Gender x Insomnia-3
Among Females
Category 1
Category 2
Category 3
Among Males
Category 1
Category 2
Category 3

Hazard
Ratio

95% HR
Confidence
Interval

MACE6

Sig

Hazard
Ratio

95% HR
Confidence
Interval

0.183
0.204

0.251
0.917

(Reference)
1.477
1.668

[0.736, 2.964]
[0.830, 3.354]

(Reference)
0.756
[0.377, 1.519]
0.811
[0.340, 1.934]

(Reference)
NS
NS

1.191
1.175

[0.652, 2.177]
[0.609, 2.265]

NS
NS

NS
**

(Reference)
0.720
[0.893, 3.193]
1.233
[0.650, 2.339]

NS
***

***
NS
B
NS
***

Gender x Insomnia
Insomnia 1 x Female
Insomnia 1 x Male
Insomnia 2 x Female
Insomnia 2 x Male
Insomnia 3 x Female

(Reference)
2.609
[1.540, 4.418]
1.477
[0.736, 2.964]
1.973
[0.925, 4.208]
1.668
[0.830, 3.354]

***
NS
B
NS

(Reference)
2.623
[1.691, 4.069]
1.191
[0.652, 2.177]
1.889
[0.986, 3.619]
1.175
[0.609, 2.265]

Insomnia 3 x Male

2.115

NS

3.234

[0.849, 5.265]

Sig

[1.653, 6.328]

Note. 'Insomnia Category 1. Low frequency of or no complaints, 'Insomnia Category 2. High frequency of
complaints, low bother Insomnia Category 3. High Frequency of complaints, high bother. '***, **, * -HR is
significant, p=<0.001, p<=0.01, p<=0.05, respectively. B - HR is borderline or close to significant, 0.05 =<p<0.1
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Summary
In summary, depressive symptoms were associated with a modest long-term risk
of CVD in both males and females. High inflammation (IL-6) was associated with
substantially higher long-term risk of CVD, particularly in males. Insomnia was not
predictive of risk of CVD in this study. In conclusion, it would be suggested that
depressive symptoms and inflammation may be considered in the future as screening
targets for risk of CVD.
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CHAPTER FIVE:
DISCUSSION
Chapter Five includes a synthesis of the study results, discussion and
implications for nursing practice and recommendations for future research. The
purpose of this study was to assess the effects of depressive symptoms, inflammation,
and quality of sleep on the risk for developing cardiovascular disease (CVD), while
additionally testing for differences among gender. The goal was to determine if any of
these factors should be considered for use in the future for routine preventative
screening for CVD risk.
Traditional Risks for CVD

This secondary analysis included a well-represented sample including, 66% females
and 34% males with a mean age of 61 years and range from 47-75 years of age. Age
was a significant predictor of MACE, which would be expected based on previously
published studies. Increasing age has an increased effect on many risk factors for CVD
such as central obesity, blood pressure, hyperlipidemia, insulin resistance,
inflammation, and endothelial dysfunction (Dhingra & Vasan, 2012; Lopez-Candales et
al., 2017; Yang et al., 2015). Men in this study were at nearly two-times the risk for
MACE. This supports previous findings with men being at a greater risk than women for
CVD within similar middle-aged populations (Maas & Appelman, 2010; Mosco, Barrett79

Connor & Wenger, 2011; Benjamin et al., 2018). However, it has been reported that
differences among the genders decrease as age increases (Maas & Appelman, 2010;
Mehta et al., 2016; Mosco, Barrett-Connor & Wenger, 2011; Benjamin et al., 2018).
While many studies have had underrepresentation of Blacks, by purposeful
oversampling, this study included 46% Blacks. Race was not a significant independent
predictor of the development of CVD within this population group.

The traditional risk factors evaluated were consistent with previous research. The
effect of smoking doubled the risk for developing MACE in this population. Our findings
support previous studies including a meta-analysis of 25 studies among varying
populations (Mons, et al., 2015). Despite the relatively small number of diabetics within
the Heart SCORE cohort (9%), nearly every model tested yielded a significant effect
from diabetes. Studies looking at the effect of diabetes on CVD have reported a 2-fold
risk of CVD when compared to non-diabetics (Anderson et al., 2001; Badescu et al.,
2016; Ivanos et al., 2018). These findings are consistent with our findings with diabetics
being at 2.3 times the risk for MACE1 and 2.08 for MACE6. Despite several studies
supporting the association between lower levels of HDL cholesterol and higher levels of
triglycerides being predictive of long-term CVD risk (Klempfer et al., 2016; Miller, 2009),
the present analysis found only minimal evidence for these relationships.
Systolic blood pressure was associated with risk for CVD in this analysis which is
consistent with evidence of systolic blood pressure being a main predictor of CVD in a
number of studies (Goldstein et al., 2014; Wong et al., 2012). Controlling blood pressure
80

at even a small range has been found to be beneficial in reducing these risks (Whelton
et al., 2017).
Novel Risk Factors
Previous literature suggests that several novel risk factors, including depressive
symptoms, inflammation, and sleep quality may influence the risk for having a major
adverse cardiac event. Additionally, prior research suggests these factors affect
outcomes and risk of mortality among those who have already developed CVD (Celano
& Huffman, 2011; Mehta et al., 2016; Rutledge et al., 2006).
The effect of depressive symptoms was of considerable interest in the present
analysis, particularly with respect to potential recommendations for both primary and
secondary prevention of CVD. The addition of depressive symptoms to the initial
traditional risk factor model increased the risk for MACE by more than 1.5 times, with
estimates generally similar between men and women. Mixed results regarding an effect
of gender and depressive symptoms have been reported. Evidence indicates a higher
prevalence of depressive symptoms in women than in men (Vaccarino & Brenner,
2016). Despite the higher prevalence rates, the effects of depressive symptoms on
MACE did not significantly differ between genders (Vaccarino & Brenner, 2016). The
present findings support similar findings reported by Ivanovs et al. (2018), where
depressive symptoms were a significant predictor in a sample of 1,500 persons HR
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1.57, 95% CI [1.06, 2.33]; p= 0.03, and significant predictor of cardiac related death HR
3.2, 95% CI [1.2, 8.9]; p=0.025 (Ivanovs et al., 2018; Lahtind et al., 2018).
Inflammation, as measured with IL-6, was strongly associated with increased
long-term risk of MACE among participants in the Heart Score cohort, especially in men.
High inflammation has been associated with higher risk for cardiovascular events and
death post event (Held et al., 2017; Nishida et al., 2011; Riker et al., 2000). The present
finding of a particularly substantial risk of MACE in men in relation to high inflammation
does not appear to have been widely reported in the literature.
Insomnia was not associated with long-term risk of CVD in this study. However,
persons with difficulty falling asleep, staying asleep, and having daytime bother have
been identified to be at higher risk for developing CVD in other studies (HoevenaarBlom et al., 2011).
Strengths and Limitations, Recommendations
The Heart SCORE data set provided a plethora of data and the advantages of
having longitudinal follow-up of risk of cardiovascular events over time. The commitment
by study participants to follow through for over 10 years helped to ensure validity of the
data. The study sample ages, gender, and racial mix were fairly balanced among the
participants which helps to aid in generalizability of results.
Study limitations include the overall good health of this community-based study
population and hence relatively low rates of MACE. The population group was obtained
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from a community population with similar backgrounds and relatively similar social
economic status and lifestyles. Although there was racially nearly equal representation
between whites and blacks, results from this population may not be generalizable to a
larger population or compared to the US population. Possible reasons for this potential
lack of generalizability included that this group was self-selected, mostly insured, had a
relatively low rate of smokers (13%) that was than the national average (14.5%)
(Benjamin et al., 2018).
Another limitation to this study is that the cut points chosen for depressive
symptoms did not reflect standard cut points used for screening. In this analysis, the
effect of depressive symptoms was significant at the highest tertile of depressive
symptoms, (CES-D) Higher (>9), This range for the highest tertile represents relatively
low scores as compared to the CESD score greater than 16 that indicates the presence
of depressive symptoms consistent with depression (Radloff, 1997; Fischer, 2009). The
lower cut points were chosen due to the sparse numbers of persons within the range of
depressive symptoms consistent with a diagnosis of depression. Specifically, in this
population, depressive symptoms were low; the mean CES-D score for women was
(8.0) and the mean score for men was (5.6). Larger samples sizes and populations with
an increased risk for CVD have been found to have increased prevalence of depression
(Piwonski, Piwonska, & Sygnowska, 2014).
The inflammatory markers, including both CRP and IL-6, were only drawn at
baseline. Using one value to predict long-term outcomes (i.e. CVD) may yield
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difficulties related to the causes of elevation from a single measurement. Both markers
are acute phase reactions, such as a recent illness or injury, and thus, an elevated IL-6
value from a single measurement may not be indicative of chronic inflammation. It
would be suggested that IL-6 be measured annually to assess for chronicity of high
inflammation.
Sleep quality was not associated with long-term risk of CVD. However, data
collection for this measure was not optimal. Specifically, there was a great deal of
missing data with this instrument, including missing data on duration of the problem.
Completing multiple self-reports on follow up visits may lead to response fatigue,
resulting in missing data and inaccurate responses (O’Reilly, 2017).
Implications for Nursing Practice
In summary, the purpose of this study was to estimate long-term risk of CVD in
relation to novel factors including depressive symptoms, inflammation, and quality of
sleep. Based on findings from this study, there are no firm global recommendations
regarding changes to screening processes for CVD risk. However, evidence from this
study showed that depressive symptoms were generally predictive of CVD in both men
and women. Therefore, because depression is associated with poorer outcomes and
mortality after a significant cardiovascular event, it is suggested that health providers,
when considering an individualized patient centered approach, maintain a keen
awareness of persons most likely to be at risk. Most screening tools for depressive
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symptoms are available for free and involve a minimum time investment. In addition to
standard risk evaluation such as the Pooled Cohort Risk Equations, providers may wish
to screen for depressive symptoms in selected individuals as part of preventative
healthcare visits.
Inflammation was highly predictive of long-term risk of CVD, especially in men.
Therefore, like depressive symptoms, screening for inflammation should be considered
on an individual basis. Screening with a laboratory test for IL-6 may prove to be a
valuable tool in the prediction of CVD, especially in men.
Although not evident in this study, the literature suggests that insomnia with long
duration and high symptoms of bother are associated with risk of CVD (Sands-Lincoln
et al., 2012). Additional evidence is needed in this area to support routine screening for
insomnia. The use of quantitative measures such as sleep actigraphy in addition to the
self-reported insomnia score may yield more accurate data.
It is recommended that the findings from this study and previous studies be
considered, when conducting risk assessments. A keen awareness of the effects of
these novel risks factors allows for individualized approached for health screenings and
educational opportunities for persons at risk.
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